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Many studies have shown that short sleep duration and/or poor sleep quality is associated with 
increasing rates of cardiovascular (CVD) mortality and morbidity. One hypothesized explanation for this 
association has been that sleep loss is a type of chronic stress that induces dysregulation of biological 
systems that ultimately increase the risk of CVD. One biological system that has been thought to link 
sleep loss and CVD is the hypothalamus-pituitary-adrenal (HPA) axis. A number of studies using small or 
convenience samples have addressed the effects of sleep deprivation on cortisol. Only a few studies have 
examined the association of habitual short sleep duration and/or poor sleep quality with changes in the 
diurnal cortisol in population based-samples; those studies vary in their methodology and in findings.  
Another biological system that has been thought to link sleep loss and CVD is the autonomic nervous 
system (ANS), through overactivation of the sympathetic nervous system (SNS) and/or probably a 
withdrawal of the parasympathetic nervous system. Experimental studies have shown an association 
between the sleep stages and markers of the sympathetic system. However, very few studies of habitual 
sleep duration/sleep quality and ANS markers have been conducted. Even fewer studies have examined 
the association of habitual sleep duration and/or sleep quality and ANS responses to a stress challenge in 
a population-based sample. The findings again have been inconsistent probably due to the use of 
different methodology and different samples. 
This dissertation used measures of salivary diurnal cortisol as well as cortisol responses to a stress 
challenge protocol to assess the relationship of habitual sleep duration and/or sleep quality with diurnal 
cortisol profile in natural conditions and in response to a stress challenge protocol in a laboratory setting. 
Diurnal cortisol was assessed from up to 16 samples of salivary cortisol for two days. Cortisol responses 
to a stress challenge were assessed from four salivary samples taken during the stress challenge that was 
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performed in a different day than the diurnal cortisol collection. To examine the relationship of habitual 
sleep duration and/or sleep quality and markers of the ANS, this dissertation used continuous 
cardiovascular measures (heart rate and heart rate variability) and four salivary amylase samples 
obtained during the stress challenge. The stress challenge included mental stress and orthostatic stress.  
Sleep duration and sleep efficiency (an objective measure of sleep quality) were assessed from 7-
day actigraphy and sleep diaries. Insomnia symptoms (a subjective measure of sleep quality) were also 
assessed using a questionnaire that included the Women’s Health Initiative Insomnia rating scale 
(WHIIRS).  
We used mixed models so as to account for the repeated measures of diurnal salivary cortisol levels 
as well as the responses (reactivity and recovery) to the stress challenge tests.   
Chapter 1 presents an introduction to this dissertation discussing the relationship between short 
sleep duration and/or poor sleep quality and CVD morbidity and mortality.  
Chapter 2 presents a systematic literature review of studies of the association between habitual 
sleep duration and/or sleep efficiency and markers of neuro-endocrine systems: HPA and ANS. These are 
plausible mechanisms that link short and/or poor sleep to CVD morbidity and mortality. 
Chapter 3 presents our analyses of the relationship between short sleep duration and/or poor sleep 
quality and features of the diurnal cortisol. We hypothesized that those participants whose slept < 6 
hours per night or whose sleep efficiency was < 85% would have higher cortisol levels on awakening, 
flatter cortisol awakening responses (CAR), and higher evening cortisol levels than participants who slept 
longer or slept better. We found that short sleepers had higher evening cortisol than the longer sleepers 
and that this association persisted after the adjustment for several known confounders. 
In chapter 4, we examined how the same groups of participants responded in terms of hormones 
(cortisol and amylase) and cardiovascular indices (heart rate (HR) and HR variability (HRV)) to a stress 
challenge test. We hypothesized that those participants who slept for a shorter time or whose sleep was 
of poorer quality would have more exaggerated responses to and less recovery from a stress challenge 
test than participants who slept longer or slept better. We found that participants with insomnia had 
exaggerated high frequency-HRV (HF-HRV) orthostatic reactivity. In an extended analysis, we found that 
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participants who slept less than 7 hours/night had exaggerated heart rate reactivity to a mental stress 
test compared to participants who slept 7 or more hours/night, but this association was attenuated after 
adjustment for naps. Paradoxically, we also found that participants who slept less than 7 hours had 
higher HF-HRV recovery from mental stress compared to longer sleepers (≥7 hours). Short sleep duration 
or low sleep efficiency was not associated with cortisol or amylase responses to the stress challenge 
protocol. 
These findings suggest that sustained high evening cortisol levels and cardiovascular responses to a 
stress challenge may be among the mechanisms linking short/poor sleep and CV disease.  
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1. CHAPTER 1. INTRODUCTION  
SLEEP DURATION AND SLEEP EFFICIENCY, THE HYPOTHALAMIC-PITUITARY ADRENOCORTICAL 
(HPA) AXIS AND THE AUTONOMIC NERVOUS SYSTEM (ANS) IN CARDIOVASCULAR DISEASE (CVD) 
Background 
There is an increasing awareness of the association between sleep duration and quality and 
cardiovascular disease (CVD). This association has been described as U-shaped as both the highest and 
lowest levels of sleep duration are associated with poorer health outcomes. In the early 1960s, the 
American Cancer Society,1 interviewed and then followed more than one million Americans and found 
that men who had reported sleeping either ≤5 hours or ≥10 hours per night had higher death rates than 
those who reported sleeping 6- 9 hours per night. Further follow up2 found that, in men, the mortality 
ratio for coronary heart disease (CHD) was higher among those who slept ≤4 hours per night (2.08) and 
among those who slept ≥10 hours per night (1.51) than among those who slept 7- 7.9 hours; in women, 
the CHD mortality ratio was also higher among those who slept ≤4 hours per night (1.10) and among 
those who slept ≥10 hours per night (1.67) than among those who slept 7- 7.9 hours. At the beginning 
of the 21st century, people in the United States reported sleeping, on the average, 7½ hours per night, 
1½ hours less than in the previous century.3 The 2009 Behavioral Risk Factor Surveillance System 
reported that among 74,571 adult respondents from 12 states, 35% of respondents sleep less than seven 
hours per day.4 Subsequent epidemiological studies have also found that people who reported either 
short or long sleep duration were at higher risk of all-cause mortality than people with sleep duration in 
the middle range.5,6  
The association between sleep duration and health, described as following a U-shape distribution (in 
which people who are in the extremes have poorer health outcomes than people who are in the middle), 
has been increasingly reported in subsequent studies. A pooled analysis of 16 published articles about 27 
cohorts,7 showed that people who slept <7 hours had a 12% greater risk, and people who slept >8 hours 
a 30% greater risk of all-cause mortality than people who slept 7- 8 hours per night.  
Cardiovascular disease (CVD) and CVD risk factors have been linked to both short and long sleep 
duration in women.8 In a meta-analysis of fifteen studies and 24 cohorts,9 short sleep duration was 
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associated with greater risk of CHD (RR 1.48, 95% CI 1.22–1.80) and stroke (RR 1.15, 95% CI 1.0-1.31) 
and long sleep duration was also associated with greater risk of CHD (RR 1.38, 95% CI 1.15-1.66) and 
stroke (RR 1.65, 95% CI 1.45-1.87) than the middle range of sleep duration. Studies have also found U-
shaped associations between sleep duration and obesity,10-12 hypertension,13 and diabetes and insulin 
resistance.14 However, a 12-year longitudinal sleep study from Netherlands, the Monitoring Project on 
Risk Factors and Chronic Diseases in the Netherlands (MORGEN) Study,15 which followed more than 
23,000 participants, linking their subjective measures of sleep duration and quality with national health 
registries, showed that short sleepers had higher risk of CVD (HR 1.15, 95% CI 1.00-1.32) and CHD (HR 
1.23, 95%CI 1.04-1.45) than normal sleepers whereas long sleepers did not have higher risk for CVD, but 
lower risk of CHD.  
The mechanisms by which both short and long sleep duration may lead to CVD and related 
outcomes are not well understood and may differ. Whereas several mechanisms have been proposed to 
account for the association of short sleep duration with CVD, long sleep duration has been proposed as 
an independent risk factor for mortality16 and as a marker of poor physical and mental health that leads 
to mortality.17 Because short sleep duration has been most often linked to CVD outcomes than long sleep 
duration, this dissertation concentrates on short sleep duration.  
Short sleep duration has been linked to clinical CVD15,18 as well as subclinical CVD, as indexed by 
coronary artery calcium19 and carotid intima-media thickness.20 Short sleep duration has also been 
associated with CVD risk factors including hypertension,13,21,22 insulin resistance,23 obesity,24 and 
diabetes.25   
In addition, poor sleep quality, assessed either subjectively through self-report measures of 
insomnia, or through objective measurements of low sleep efficiency on actigraphy or reduced time in 
slow wave sleep (SWS) on polysomnography, has also been associated with adverse CVD outcomes. For 
example, insomnia has been associated with increased rates of myocardial infarction,26 and self-reported 
sleep quality on the Pittsburgh Sleep Quality Index has been linked to the metabolic syndrome.27 In a 
cohort of older, mostly white, men, reduced time in SWS has been associated with hypertension28 and 
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obesity. 29 Low sleep efficiency has also been associated with elevated blood pressure among healthy 
adolescents.30  
In the MORGEN study,15 participants with both short sleep duration and poor sleep quality had a 
63% higher risk of CVD than those with normal sleep duration and good sleep quality. In particular, it has 
been suggested that short sleep duration is more strongly associated with cardiometabolic outcomes 
when it is accompanied by insomnia symptoms than when it is not.31-33 
Two mechanisms that are thought to link short sleep duration and/or poor sleep quality with CVD 
outcomes are dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis leading to alterations in 
diurnal cortisol profile, and dysregulation of the autonomic nervous system (ANS) in which its 
sympathetic branch may be overactivated or its parasympathetic branch may not modulate the excessive 
activity of the sympathetic branch. These systems are also involved in the response to stress, and sleep 
deprivation is considered a type of chronic stressor.34,35 Alterations of the HPA and SNS are not the only 
mechanisms by which short sleep duration and/or poor sleep quality may lead to higher risk of CVD and 
related outcomes. Whereas the HPA and SNS interact and reinforce each other during emotional stress, 
cortisol and catecholamines also initiate an inflammatory response, and acute and chronic stress can 
trigger an inflammatory response initiated centrally in the brain.36 Both inflammatory and immunologic 
biomarkers may also be found in the pathway between short/poor sleep and CVD (Supplemental Figure 
A-1). Interactions between the HPA and SNS, along with inflammatory biomarkers and metabolic factors, 
may play a key role in the association of sleep with CVD and related outcomes.34,37  
Physiology of the neuroendocrine stress systems 
The physiological response to stress involves release of adrenocorticotropic hormone (ACTH) from the 
anterior pituitary, cortisol from the adrenal cortex, epinephrine from the adrenal medulla, and 
norepinephrine from the sympathetic nerves.38 The production of catecholamines (epinephrine and 
norepinephrine) is regulated by the sympathetic nervous system (SNS). The HPA axis and the SNS 
interact and reinforce each other during emotional stress,  in which corticotropin-releasing hormone 
(CRH) stimulates the synthesis and secretion of ACTH, and norepinephrine potentiates these effects.39 
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Glucocorticoids also regulate catecholamine biosynthesis in the adrenal medulla, and catecholamines 
stimulate ACTH release from the anterior pituitary gland.38 
The Hypothalamic-Pituitary-Adrenal (HPA) Axis  
The HPA axis and CVD 
Dysfunction of the HPA, as indexed by increases of urinary cortisol levels or alterations in diurnal 
cortisol profile, predicts CVD mortality. For example, a cohort study of more than 800 elderly people 
found that those with higher urinary cortisol levels had higher risks of CVD mortality.40 Alteration in 
diurnal salivary cortisol profile has also been associated with cardiovascular-related mortality and with 
subclinical CVD. A large epidemiological study of more than 4000 public workers41 showed that flatter 
slope in cortisol levels was associated with higher risk of cardiovascular mortality. Flatter diurnal salivary 
cortisol slopes have also been associated with the presence of coronary artery calcification.42 Higher 
diurnal total salivary cortisol levels have also been associated with higher numbers of plaques on carotid 
arteries.43 These studies suggest a role of cortisol in atherosclerosis. 
Cortisol responses to an acute psychological stress in laboratory have also been studied as proxies 
for the mechanism by which mental stress is associated with CVD. Exaggerated cortisol responses to a 
mental stress have predicted subclinical CVD and CVD risk factors, such as coronary artery calcification44 
and its progression.45 Cortisol reactivity (cortisol response to i.e. a mental stress in laboratory settings) 
has also been associated with greater risk of hypertension.46  
 Sleep and the HPA axis   
Experimental and observational studies of the relationship of sleep duration and/or sleep quality with 
the HPA axis have shown inconsistent results, maybe in part because of differences in sample and 
measurement approaches. Experimental studies in which volunteers underwent total or partial sleep 
deprivation have been limited to small samples and specific groups such as only women or only men. For 
example, in a study of 33 young men,47 evening plasma cortisol levels were higher after a night of sleep 
deprivation than after a night of normal sleep. Similarly, in another study of 11 healthy young men,48 
evening salivary cortisol levels were higher after a night of partial sleep deprivation than after a night of 
normal sleep. Another study of 17 healthy young women49 found reduced salivary morning cortisol levels 
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30 minutes after awakening, elevated afternoon/evening cortisol and slow decline of cortisol levels from 
morning to evening following a single night of sleep restriction. However, in another study of healthy 
young men,50 diurnal plasma cortisol levels were lower after a night of sleep deprivation than after a 
night without sleep deprivation. Similarly, in a study of 13 young women who were exposed to sleep 
disturbance during three consecutive nights,51 the cortisol awakening response (CAR) after disturbed 
nights was not different from that after undisturbed nights.   
Epidemiological studies of the relationship between sleep duration and/or sleep quality and cortisol 
levels are few and they also have few consistent results as we will discuss in the next chapter.  
Markers of the Hypothalamic-Pituitary-Adrenal (HPA) Axis 
Free cortisol (the cortisol that is not bound to glucocorticoid receptors) is a marker of the HPA axis 
that can be detected in blood, urine and saliva. Salivary cortisol sampling is most convenient for 
epidemiological studies because it is a non-invasive marker of the HPA function and it is feasible to collect 
it for several times a day for more than one day. Cortisol levels in plasma and saliva rise and fall 
throughout the 24-hour sleep-wake cycle, reaching a nadir 2-4 hours before the onset of sleep.52 They 
rise about 50-75% within the first 30 minutes after awakening; this pattern is called the cortisol 
awakening response (CAR).53 In the next 2-3 hours after awakening, cortisol levels decline sharply; 
during the rest of the day, levels continue to fall but more gradually.52,54  
Cortisol levels also respond, of course, to stress. In the laboratory, cortisol responses to mental 
stress tests (e.g., the Trier Social Test (TSST),55 the color-word conflict task,56 and the arithmetic task57 
have been investigated as proxies for the effect that acute stress has on the HPA axis function.  
The Autonomic Nervous System (ANS)   
The ANS and CVD 
Epidemiological studies have shown that increased heart rate (the result of the joint influence of 
sympathetic and parasympathetic nervous system on the sino-atrial node), both at rest and in response 
to exercise, can predict cardiovascular mortality.58,59 Studies of cardiovascular reactivity to stressors have 
evaluated the activation of the autonomic nervous system in response to stress challenges as well as the 
effects of stress responsivity on the cardiovascular system. For example, in the CARDIA study, blood 
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pressure reactivity during psychological and physical stress predicted hypertension 13 years later among 
black and white men and women.60 In the same group of participants, blood pressure reactivity to mental 
stress (video game) predicted the presence of coronary calcium.42 
Sleep and the ANS 
Experimental studies have consistently showed that sleep regulates sympathetic activity. Circulating 
levels of norepinephrine and epinephrine have been studied in different stages of sleep, and periods of 
wakefulness before and after sleep. Plasma concentrations of both catecholamines are lower during sleep 
than during the periods of wakefulness (before, during or after sleep).61 In experimental studies, plasma 
catecholamine levels were higher during the hours of the nights that subjects were awakened than when 
they were not, and the lowest level of plasma norepinephrine was during the slow wave sleep (SWS).62 
Similarly, heart rate and blood pressure, which are normally influenced by the SNS, were lower during 
stage 2 and SWS than in other sleep stages or wakefulness.63 Insomnia, a disorder characterized by 
perceived difficulties in initiating or maintaining sleep, a state of “hyper-arousal,”64 has been associated 
with abnormalities in autonomic nervous system activity.65,66  
Cardiovascular reactivity to stressors has been examined in a few experimental studies; most of 
them with small samples of healthy volunteers who underwent sleep deprivation before the mental stress 
challenge. Some have found associations between sleep deprivation and autonomic alterations,67,68 but 
others have not.69  
Markers of the Autonomic Nervous System (ANS) 
Catecholamine levels in plasma and urine reflect activation of the SNS.38 Although techniques such 
as microneurographic measurement of muscle sympathetic nerve activity and organ specific 
norepinephrine spillover70 are more specific and reliable, they are not useful for large population studies. 
Measures that are commonly used in epidemiological studies include blood pressure, heart rate (HR), 
blood pressure and HR variability, and most recently salivary amylase.71 Sympathetic activation results in 
the secretion of parotid saliva with high concentrations of amylase and low flow rates, whereas 
parasympathetic activation results in saliva with low concentrations of amylase and high flow rates.72 
Studies have found associations between salivary alpha amylase (sAA) release after psychological and 
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physical stress and indicators of sympathetic activity, such as plasma norepinephrine73 and shortened 
cardiac pre-ejection period.74 sAA has been proposed as a useful and novel stress marker75 because it 
responds to stress and it is simple to collect. 
Summary 
The relationship between alterations in sleep and both the HPA and the SNS have been examined in 
many experimental studies in which small samples of healthy participants in their 20s, only women, or 
only men were exposed to acute sleep deprivation or interruption. Abnormal sleep patterns, such as short 
sleep duration and poor sleep quality and their association with these two stress systems have not been 
studied extensively in community-based samples under habitual sleep conditions. 
Statement of Purpose 
Although sleep duration and quality are associated with cardiovascular disease and related outcomes, the 
mechanisms of this association have not been determined. Several mechanisms that are thought to be 
involved in this association include dysfunction of the HPA, dysregulation of the autonomic nervous 
system (in which the sympathetic and parasympathetic nervous system are unbalanced), and increases in 
inflammatory biomarkers and metabolic factors. The interactions of the hormonal and inflammatory 
systems along with the metabolic factors may play an important role (Supplemental Figure A-1) in the 
association of short/poor sleep and poor health, specifically CVD. The INTERHEART study, a case-control 
study about potentially modifiable risk factors for myocardial infarction (MI) conducted in 52 countries, 
reported that nine risk factors (including smoking, lack of exercise and lack of consumption of fruits and 
vegetables, as well as, hypertension, obesity and diabetes among others) accounted for about 90% of 
the risk for acute MI.76 The population attributable risk (99% CI) for the nine potentially modifiable risk 
factors was 88% (84-91) for older adults both men and women. This finding suggests that approximately 
10% of the risk of acute MI remains to be explained by other potentially modifiable risk factors. Perhaps, 
short sleep duration and/or poor sleep quality could also enter in the list of preventable MI risk factors in 
the near future. 
The purpose of this study was to examine some of the possible mechanisms involved in the 
relationship of short sleep duration and/or poor sleep quality with CVD in a sample of participants from 
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the Multi-ethnic study of atherosclerosis, the MESA study. Data from two MESA ancillary studies (Sleep 
and Stress) were linked in order to study these associations. We predicted that participants who have 
either short sleep duration or poor sleep quality or both would have alterations in both HPA and SNS 
functions. We also assessed the role of race and socioeconomic status as possible moderators of this 
association. Studies have suggested that African-Americans had poorer health-related quality of life than 
Whites as a result of frequent snoring, insomnia symptoms and excessive daytime sleepiness.77 In the 
MESA Study, African-Americans had 5 times, Asian-Chinese had 2.3 times, and Hispanics had 1.8 times 
higher odds of short sleep duration compared to Whites.78 The sleep deficits in this group maybe the 
result of socioeconomic status and social support differences across these racial/ethnic groups. 
We studied sleep and markers of the HPA and SNS in an ethnically mixed study population. MESA is 
a large population-based multiethnic cohort study with a variety of measures at several time points. The 
MESA Sleep Study obtained measures of habitual sleep duration and sleep quality through direct 
monitoring with both seven-day actigraphy and one-night home polysomnography (PSG). The MESA 
Stress Study collected up to 16 measures of cortisol over 2 days and four salivary cortisol samples during 
a stress challenge. It also collected measures of sympathetic/parasympathetic activation (heart rate, 
blood pressure, heart rate variability and salivary alpha-amylase) under resting conditions and in 
response to a standardized stress challenge protocol. These two ancillary studies were conducted in 
largely overlapping subsets of the MESA cohort at Exam 5.  
We investigated the associations between chronic, habitual short sleep duration and poor sleep 
quality and two neuro-endocrine (HPA and SNS) systems in these MESA datasets.  
The specific aims of this dissertation proposal were: 
Aim 1: To examine the associations of sleep duration and sleep quality with diurnal patterns in 
salivary cortisol using data from 7-day actigraphy-based measures of sleep duration and sleep quality and 
≤16 measurements of salivary cortisol. 
Hypothesis 1a:  Participants with short sleep duration will have a lower cortisol awakening response 
(CAR), and shallower cortisol decline during the day than participants with longer sleep duration, before 
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and after control for age, gender, race/ethnicity, socioeconomic, psychosocial and behavioral factors, 
medications, apnea, and sleep quality. 
Hypothesis 1b: Participants with poor sleep quality will have a lower cortisol awakening response 
(CAR), and shallower cortisol decline during the day than participants with better sleep quality, before 
and after control for age, gender, race/ethnicity, socioeconomic, psychosocial and behavioral factors, 
medications, apnea, and sleep duration. 
Aim 2: To examine the association of sleep duration and sleep quality with measures of hormonal 
and cardiovascular markers, in response to and recovery from a standardized stress challenge protocol.   
Hypothesis 2a:  Participants whose sleep was short or of poor quality would have higher level heart 
rate (HR) and higher value of amylase and cortisol  at baseline and lower level high-frequency heart rate 
variability (HF-HRV) at baseline than individuals who slept longer or better. 
Hypothesis 2b:  Participants whose sleep was short or of poor quality would have greater HR and 
greater amylase and cortisol reactivity and reduced HF-HRV reactivity to mental and orthostatic stress 
challenges than individuals who slept longer or better. 
Hypothesis 2c:  Participants whose sleep was short or of poor quality would have slower HR, HF-
HRV, and slower amylase and cortisol recovery from stress to baseline than individuals who slept longer 
or better.   
Aim 3: To test for interaction in the association between short sleep duration and/or poor sleep 
quality and cortisol with gender, race/ethnicity, and SES. 
Hypothesis 3a:  This relation differs by race/ethnicity, with stronger association among African 
Americans and Hispanics compared to whites. 






2. CHAPTER 2. A SYSTEMATIC REVIEW OF THE LITERATURE 
THE RELATIONSHIP BETWEEN SLEEP DURATION AND/OR SLEEP EFFICIENCY AND THE 
HYPOTHALAMIC-PITUITARY ADRENOCORTICAL (HPA) AXIS AND THE AUTONOMIC NERVOUS 
SYSTEM (ANS) 
Background 
Numerous studies have shown associations between short sleep duration and/or poor sleep quality and 
cardiovascular (CVD) outcomes. Among the mechanisms that may be involved in these associations are 
dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis and/or overactivation of the sympathetic 
nervous system (SNS). 
Most studies of the associations of short and/or poor sleep with dysfunction of the HPA and 
hyperactivation of the SNS have been conducted under experimental conditions of acute curtailment of 
sleep or sleep interruptions. Apparently, few epidemiological studies have examined these associations, 
and these studies have used different methodologies making comparability across them difficult. For 
example, some studies have used urinary cortisol,79 whereas others have used salivary cortisol.80,81 The 
protocol of salivary cortisol collection has varied in timing of sample collection during the day, and 
number of samples collected per day, as well as, number of days of collection. 
The experimental studies dealing with the effects of acute sleep deprivation on the HPA and SNS 
markers have been conducted in specific populations: healthy young adults, only men48 or only women.49 
The effects that sleep deprivation produces in the neuroendocrine systems of these study participants 
may differ from the effects of habitual chronic sleep loss in an older population like MESA participants. A 
few studies to date have focused on habitual short sleep duration and/or poor sleep quality and diurnal 
cortisol in community-based samples.79-81 Most of these studies have also used only subjective measures 
of sleep,80,81 which may not correlate very well with objective measures of sleep; for example subjective 
sleep duration may be overestimated.82,83  
In addition, only a few studies have evaluated how short sleep duration and/or poor sleep quality 
affects the cardiovascular and hormonal responses to a stress challenge test. Most of these studies have 
been done in sleep laboratories and have used different types of challenges. Some studies have used 
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mental stress tests, such as the Trier social test,55 while others used physical stress tests, such as the 
isometric handgrip exercise.84 The response to stress may depend on the type of task participants 
perform; therefore studies in which participants perform more than one task may be preferable to those 
involving a single task.85 The cardiovascular outcomes assessed also vary and most studies have used 
more than one cardiovascular measure, i.e. hear rate, heart rate variability or blood pressure. Using 
several measures of cardiovascular response in a given study may also help to increase consistency in the 
results.86   
The goal of this systematic review was to determine if short sleep duration and/or poor sleep quality 
may be associated with alterations of the diurnal cortisol profile and of the cardiovascular and hormonal 
responses to a stress challenge test in epidemiological studies as experimental studies have found. We 
conducted three systematic reviews to study: (1) sleep duration and/or sleep efficiency and diurnal 
cortisol, (2) sleep duration and/or sleep efficiency and cardiovascular responses to a stress challenge, and 
(3) sleep duration and/or sleep efficiency and hormonal responses to a stress challenge. We included 
only studies in which the exposure was habitual sleep; sleep in the participants’ current environment. 
Studies of deprivation of sleep were not included because they are usually conducted in experimental 
conditions rather than in everyday life. In addition, sleep deprivation studies usually recruit only young 
and healthy volunteers probably because they are more readily available. We included sleep deprivation 
only if we did not find any study in any of the categories above. Although the stress challenge is 
conducted in laboratory settings, it is a method of measuring the outcome, not the exposure.  
Methods 
Articles in the systematic review for the three subsections described below were identified through two 
databases: OvidMedline and Web of Science. The inclusion criteria were: 1) original research studies 
published in scientific journals on paper or online between 1995 and 2015, 2) English language, 3) 
”healthy” adult humans, 4) alterations of the diurnal cortisol profile and/or cardiovascular and hormonal 
responses to a stress challenge test were the primary outcomes, rather than secondary outcomes or 
covariates, 5) sleep was measured under “normal ”habitual conditions (in the home environment), 6) 
sleep was objectively measured or subjectively measured using scales already validated, and 7) the 
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analyses were at least correlational and controlled for the demographic variables that are known 
confounders of the relationship between sleep duration/sleep efficiency and cortisol. We excluded studies 
1) that involved manipulation of sleep duration or quality such as sleep deprivation or sleep interruption, 
2) that examined short sleep duration and or poor sleep quality associated with burnout or fatigue, and 
3) that involved a specific health condition such as cancer or Cushing syndrome.   
Sleep duration/sleep efficiency and diurnal cortisol  
The search terms included “salivary cortisol” or “saliva cortisol” or “urinary cortisol” or “diurnal cortisol” or 
“diurnal cortisol profile” or “diurnal cortisol pattern” and “sleep duration” or “sleep efficiency” or “sleep 
quality” or “insomnia” or “difficulty falling sleep.” We filtered our search to adult humans, English 
language and publications only in the last 20 years. 
We found 365 articles. These articles were imported to Covidence©, a free online software useful for 
systematic reviews, in which we conducted the qualitative review through the following steps (see also 
Figure 2-1):  
1. We screened the titles and abstracts for relevance (206 articles were irrelevant and 6 duplicate) 
2. We screened the full text and excluded134 articles due to:  
a. Wrong study population (e.g., pediatric population or pregnant women) (N=29),  
b. Experimental sleep studies (e.g., sleep deprivation) (N=35) 
c. Wrong setting, such as burnout and fatigue (N=25),  
d. Health problems such as cancer, depression, obesity, Cushing, and PTSD (N=15) 
e. Articles not published in journals (e.g., conference abstracts) (N=12) 
f. Cortisol as secondary outcome or covariate (N=8) because the cortisol outcomes were 
described but not analyzed 
g. Only very simple analysis, such as t-test (N=1);  
h. Shift workers (N=6)  
i. Non-original research, such as reviews (N=3) 
3. We systematically extracted information from the 19 articles included, specifically: sample size, 
characteristics of the population studied, study design, cortisol sampling and derived cortisol variables, 
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statistical methods applied, sleep measures, and major significant findings. This information is shown in 
Table 2-1. 
Sleep duration/sleep efficiency and cardiovascular responses to a stress challenge test   
For the searching of cardiovascular responses to a stress challenge associated with sleep, we used the 
same inclusion criteria as in the previous section.  
1. We first performed four separated investigations. We searched on the following groups (see 
Figure 2-2):  
Group 1: “Heart rate” and “sleep” and “stress reactivity” (N= 67)  
Group 2: “Heart rate” and “sleep” and “stress recovery” (N=71) 
Group 3: “Heart rate variability” and “sleep” and “stress reactivity” (N=34)   
Group 4: “Heart rate variability” and “stress” and “recovery” (N=38) 
2. Then, we joined these four groups and deleted duplicate articles ending with 122 articles, which 
were imported to Covidence©. 
3. After screening titles and abstracts, we excluded 79 irrelevant articles. 
4. After screening full text to assess for eligibility, we excluded 41 articles due to: 
a. Wrong settings (N=34),  
b. Wrong patient population (N=7)    
Out of the two studies included in the qualitative review, only one study87 involved sleep under 
habitual conditions. To our knowledge, this is the first article that studied the association between short 
sleep duration under habitual conditions and cardiovascular responses to mental stress. We included in 
this literature review a second study88 that involved sleep deprivation. We decided to include it in the 
review because it was the only study that used orthostatic stress as a task in the stress challenge (see 
Table 2-2).  
Sleep duration/sleep efficiency and hormonal responses to stress 
For these search, we conducted two parallel searches as in previous section, one involving salivary 
cortisol responses to a stress challenge and the other involving salivary amylase responses associated 
with sleep. For cortisol, the search terms included “salivary cortisol” and “sleep” and “stress reactivity” 
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or “stress recovery” or “stress challenge” or “stress.” For amylase, the search terms included “salivary 
amylase” and “sleep” and “stress reactivity” or “stress recovery” or “stress challenge” or “stress.”  
We then joined the two search findings and after deleting duplicates, we identified 53 potential 
articles to include in our qualitative review. The 53 articles were imported to Covidence©, in which we 
conducted the systematic review following the same steps than before: 
1. First, we screened by titles and abstracts and excluded 31 irrelevant articles. 
2. Then, we screened the full text to assess for eligibility and excluded 21 articles due to the 
following reasons: 
a. Wrong study design (N=6),  
b. Wrong settings (N=6),  
c. Non-published articles (N=3),  
d. Wrong patient population (N=4), and  
e. Sleep deprivation/restriction (N=2).  
Only one article qualified to be included in the qualitative review.89 However, we also included the 
two studies of sleep deprivation because of lack of studies in this topic. The sample characteristics, study 
design, analytical approach, and outcome measures, are shown in Table 2-3. 
Results 
Sleep duration/sleep efficiency and diurnal cortisol 
Out of the 19 articles (Table 2-1) that were included in the qualitative review, sixteen studies (84%) were 
cross-sectional studies, only one study was longitudinal90 and two were case-control studies.91,92 Only six 
(32%) studies were done in North America. Sample sizes among the studies varied substantially. Four 
studies had a sample size >450 subjects,80,81,93,94 the rest had fewer subjects with four having a sample 
size <50. Only six studies (32%) examined sleep duration as one of the main exposures (See 
Supplemental Table B-1), and only four of them used an objective measure of sleep duration. All studies 
examined sleep quality using objective measure such as PSG (5 studies) or actigraphy (4 studies) or both 
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(1 study), and/or subjective sleep measures using questionnaires (12 studies) such as the Karolinska 
Sleep Diary, the Pittsburgh Sleep Quality Index, or logbooks (See Supplemental Table B-2).  
Four (21%) studies measured urinary cortisol with three of them using 24-hour urinary collection. 
Fifteen studies (79%) measured salivary cortisol. The number of days, number of samples per day and 
timing of salivary cortisol collection varied across the studies. The specimens were in general collected on 
weekdays, although in one study the collection was on a non-working day.95 The number of days of 
collection varied between one and seven days. The number of samples collected per day also varied 
between one to ten samples per day. The total number of samples per collection was between 2 samples 
(three studies),81,92,94 and 21 total samples (one study).91   
Among the studies that used salivary cortisol, the derived cortisol variables used also varied. Only a 
few studies used features of the diurnal cortisol profile in their analysis (awakening, CAR and 
slope).80,81,91,93,95-97 The others used time points of collection or only morning cortisol. The analytical 
approaches used for these 19 studies were also diverse. Seven studies used mixed models80,81,90,95,96,98,99  
whereas the other studies applied linear regression, ANOVA, or correlational analysis.  
Sleep duration/sleep efficiency and cardiovascular responses to a stress challenge  
We only found one study in this qualitative review and it is showed in Table 2-2. This study examined 
responses to mental stress87 looking at the association between total sleep time and cardiovascular 
responses to a stress challenge in 79 undergraduate male students. Participants performed Stroop, MSIT, 
and speech preparation and delivery tasks, and their heart rate (HR), HR variability and blood pressure 
responses to the stress were evaluated. In linear regression, shorter sleep duration was associated with 
greater reduction in HF-HRV during and elevated diastolic blood pressure following the stress task. 
Additionally, we included in this table an experimental study88 as mentioned above. This study 
examined the association of sleep deprivation with cardiovascular responses in a healthy group of 16 
young (range 20-28 years) and old (60-69 years) adults, all normotensives. The study found that sleep 
deprivation did not affect heart rate or diastolic blood pressure responses to orthostatic stress and 
attenuated the systolic blood pressure orthostatic response.    
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Sleep duration/sleep efficiency and hormonal responses to a stress challenge 
We also found only one article89 that studied sleep under habitual conditions and hormonal responses to 
a stress challenge. Subjects were 53 women; measures of sleep were 7-day actigraphy and subjective 
measures of sleep duration and quality the day before the stress test; with the outcome that was cortisol 
responses to a stress challenge. Participants performed a battery of 6 Stroop color-word interference 
tasks and cortisol was collected at 4 points: baseline, post stress, and 30 and 45 minutes after the end of 
the stress challenge. Objective measures of sleep quality the night before the stress challenge were 
associated with cortisol reactivity; participants with lower sleep quality displayed a blunted cortisol 
response compared to participants with higher sleep quality. This information has been extracted and is 
showed in Table 2-3. 
Additionally, because the literature on these associations using sleep measures in the home 
environment is scarce, we extracted information from two experimental studies100,101 that used sleep 
deprivation and added them to this table. One of these studies100 examined the effect of sleep 
deprivation on salivary cortisol and amylase responses, and found higher salivary cortisol response in the 
sleep deprived group than in the normal sleep group. Salivary amylase response was elevated in all 
participants, but the groups did not differ. In the second study101 in young healthy students, sleep 
restriction was associated with increased amylase at baseline but no differences in amylase response 
between the restricted sleep and normal sleep groups. 
Discussion 
The association of short sleep duration with changes in diurnal cortisol was found in only one study. The 
association of poor sleep quality with diurnal cortisol changes was more consistent than the association of  
sleep duration with diurnal cortisol. We found only two studies of hormonal and cardiovascular responses 
to stress challenge in subjects with habitual short sleep duration and/or poor sleep quality compared to 
subjects with normal sleep. This literature review shows that there is a lack of studies of the association 
of habitual sleep duration and/or sleep quality and the HPA axis and ANS system, and that the 
epidemiological studies examining these associations differ in sample size, protocol of salivary cortisol 
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collection and how they measured both cortisol and sleep; all of this leading to few consistencies in their 
results. 
Diurnal salivary cortisol is a useful tool for epidemiological studies because it is feasible to obtain in 
large numbers of participants, the instructions are simple to follow, the collection can be done several 
times per day with little burden for participants, and compliance is acceptable.102 However, using diurnal 
salivary cortisol as the outcome has some pitfalls that make the findings across studies difficult to 
compare. First, the non-linear pattern of diurnal cortisol secretion makes the protocol of salivary cortisol 
collection very complex. Studies with only one or two samples over the course of a day cannot produce 
reliable measures of diurnal cortisol. The measurement of salivary cortisol only in the morning and with 
less than three samples per day does not give enough information about the peak and changes of 
trajectory of diurnal cortisol. It has been suggested that the minimal salivary collection protocol should 
involve at least one sample at awakening, one at the peak of the CAR and one at bedtime.103 Indeed, one 
day of salivary cortisol sampling produces results less reliable than several days of sampling. The more 
days on which samples are collected in a specific study the better the controlled for day-to-day 
variability.104 On our literature review, almost all studies followed different protocols for salivary cortisol 
sampling collection differing in the number of salivary samples collected per day and in the timing of 
collection during the day (See Table 2-1).  
In addition, studies also varied in the computation of the features of the diurnal cortisol profile 
(Supplemental Table B-1 and Supplemental Table B-2). Some studies averaged samples at time points 
others examined the deviations of cortisol during day (e.g., CAR or slope of the diurnal curve). Classically, 
cortisol has been analyzed using the area under the curve (AUC) for the total cortisol over the day. Most 
recently, studies have focused on components of the curve (CAR and slope), which have been associated 
with diseases. For example, higher CAR has been found in patients with depression compared to non-
depressed persons.105,106 Flattened diurnal cortisol has also been associated with mortality among 
patients with breast cancer,107 and with cardiovascular disease.41  
Few papers identified for all the searches included large sample sizes. One of the two largest studies 
in this review was the Whitehall II Study,80 a cohort of 2979 London-based civil servants that used 
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subjective measures of sleep duration and quality and collected up to 6 cortisol samples per day. The 
study found an association between short sleep duration and increased salivary cortisol awakening 
response (CAR), and a shallower downslope in cortisol levels, as well as between sleep disturbance and a 
shallower downslope in cortisol levels. The second largest study of this review, the Danish study81 of 
4066 civil servants also used subjective measures of sleep quantity and quality and initially collected only 
3 samples per day, the first sample 20 minutes after awakening. The study did not find an association 
between sleep duration and diurnal levels in cortisol, but it found inverse associations between sleep 
problems and morning cortisol. A subsample of this study, 387 participants, was reexamined 3 months 
later using same sleep parameters but with an extra salivary sample (at awakening). The study found 
that those with sleep problems had a flattened cortisol profile. The Whitehall II study included more men 
than women and a low percentage of ethnic minorities,108 and the Danish study included mostly white 
people and a larger percentage of women than men.81 As a result, the findings of these two studies may 
be generalizable only to similar populations.  
A very few studies of sleep in habitual conditions have evaluated how habitual short sleep duration 
and/or poor sleep quality affects cardiovascular (heart rate, heart rate variability) and hormonal (cortisol 
and amylase) responses to a stress challenge test. Sleep loss may potentiate the effect of the stressors 
on the cardiovascular and hormonal indices. These outcomes (indices of the HPA and ANS function) are 
also important because people who have short sleep duration and/or poor sleep quality have to deal with 
different stressors when they face real life situations in everyday life.  
We found only one study87 examining the association between short sleep duration in habitual 
conditions and cardiovascular responses to acute stressors. This study found that short sleep duration 
was associated with greater reduction in HF-HRV during stress. Also few experimental studies have 
examined this association, in which participants underwent sleep deprivation. These studies were done in 
small samples of healthy young volunteers, and followed different stress challenge protocols. For 
example, one study showed an increase in heart rate variability during mental stress among 18 study 
participants who underwent acute total sleep deprivation.67 In another controlled experimental study68 of 
20 healthy adults, the stress challenge test had a stronger effect on blood pressure reactivity but not with 
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heart rate in the subjects with a night of total sleep deprivation than with a night of normal sleep. In a 
most recent study, a randomized crossover study, 28 subjects had greater heart rate reactivity to and 
slower recovery from mental stress  after 24 hours of total sleep deprivation than when they were not 
undergo sleep deprivation.109  
In addition, we only found one study89 that examined the association of habitual sleep quantity and 
sleep quality with cortisol responses to a stress challenge. This study was limited to a small sample of 
young-adult females and found that low sleep quality was associated with a blunted cortisol response. In 
experimental studies, one study100 found sleep deprivation associated with higher cortisol reactivity to 
stressors and no association of sleep deprivation with salivary amylase response. 
Conclusions 
In total 19 epidemiological studies have examined habitual short sleep duration and/or poor sleep quality 
with diurnal salivary cortisol and only a couple have examined these sleep characteristics in relation to 
responses to a stress challenge. The current evidence of the association of habitual sleep duration and 
dysfunction of the HPA is not consistent especially because most of the studies have small sample sizes, 
the larger samples lack generalizability, and the salivary collection protocols and the cortisol indicators 
used in analysis vary among the studies. The association of sleep quality with diurnal salivary cortisol is 
more consistent than that the association of sleep duration with diurnal salivary cortisol; despite the 
variations in sampling methods. Practically, no studies have addressed the associations of habitual sleep 
duration/sleep quality and hormonal and cardiovascular responses to a stress challenge in a 
heterogeneous sample population. This area needs more investigation. 
Data on habitual sleep in community-based samples are sparse. The few existing studies suggest 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































* The cortisol outcomes were described but not analyzed in the papers. 
** The analysis involved a simple t-test and no adjustment for covariates.  
Articles identified through database search (n = 365) 
Full-text articles assessed for eligibility (n = 153) 
19 articles included in the systematic review 
Excluded by title and abstract: 
Irrelevant (n = 206) 
Duplicated articles (n = 6) 
Excluded articles: 
Wrong study population (n = 29) 
Experimental sleep studies (n = 35) 
Wrong settings (n = 25) 
Health problems (n = 15) 
No published article (n = 12) 
Cortisol as a secondary outcome* (n = 8) 
Very simple analysis** (n = 1) 
Shift workers (n = 6) 
Reviews (n = 3) 
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Figure 2-2. Flow Chart of articles selected for sleep duration/sleep efficiency and cardiovascular 



















*Group 1: “Heart rate” and “sleep” and “stress reactivity;” Group 2: “Heart rate” and “sleep” and “stress recovery;” 
Group 3: “Heart rate variability” and “sleep” and “stress reactivity;” and Group 4: “Heart rate variability” and “stress” 
and “recovery”   
 
  
Articles identified through database search (groups)*: 
 Group 1 (n = 67) 
 Group 2 (n = 71) 
 Group 3 (n = 34) 
 Group 4 (n = 38) 
 
Full-text articles assessed for eligibility (n = 43) 
2 articles included in the systematic review 
Excluded by title and abstract: 
Irrelevant (n = 79) 
Excluded articles: 
Wrong study population (n = 7) 
Wrong settings (n = 34) 
 
After joining the 4 groups and deleting duplicates (n = 122) 
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3. CHAPTER 3. ASSSOCIATIONS OF SLEEP DURATION AND QUALITY WITH ACTIVATION OF 
THE HYPOTHALAMIC-PITUITARY ADRENOCORTICAL (HPA) AXIS 
Abstract 
Context: Short sleep duration and poor sleep quality are associated with cardiovascular outcomes. One 
mechanism proposed to explain this association is altered diurnal cortisol secretion.  
Objective: To examine the associations of sleep duration and sleep efficiency with diurnal salivary cortisol 
levels, taking insomnia and other factors into account. 
Design: Cross-sectional analysis using data from the Multi-Ethnic Study of Atherosclerosis (MESA), a 
population-based study. In 2010-2012, actigraphy-based measures of sleep duration and efficiency and 
up to 16 diurnal salivary cortisol samples over 2 days were collected in white, African-American, and 
Hispanic study participants aged 54-93 years old (n = 600 with analyzable data). Piecewise mixed linear 
models were used to assess the associations of sleep parameters with components of the daily cortisol 
profile. We adjusted the models for time of wake-up, day of salivary collection, age, gender, 
race/ethnicity, income-wealth index, behavioral factors, chronic health problems, and other sleep 
characteristics. 
Results: Shorter average sleep duration (<6 hours/night) was associated with less pronounced late 
decline in cortisol (2.2% difference in slope; 95% CI 0.8 to 3.7; P≤0.01) and a less pronounced wake-to-
bed slope (2.2% difference; 95% CI 1.0, 3.4; P ≤0.001) compared to longer sleep duration (≥6 
hours/night). Lower sleep efficiency (<85%) was associated with less pronounced early decline in cortisol 
(29.0% difference in slope; 95% CI 4.1, 59.7; P <0.05) compared to higher sleep efficiency (≥85%). 
Study participants reporting insomnia (n=209) had a flatter cortisol awakening response (CAR) (−16.1% 
difference in slope; 95% CI −34.6 to −0.1; P <0.05) than those without insomnia. 
Conclusions: Shorter sleep duration, lower sleep efficiency, and insomnia are associated with alterations 





Cardiovascular disease (CVD) has been one of the major health outcomes linked to short sleep 
duration. Women with self-reported sleep duration of ≤ 5 hours per night had higher risk of CHD than 
women who slept 8 hours per night. 8,18 Short sleep duration has also been associated with CVD risk 
factors including hypertension,13 diabetes,116,117 and obesity.12,118 Subclinical CVD as indexed by coronary 
artery calcium (CAC) and carotid intima-media thickness (CIMT) has also been linked to short sleep 
duration. In the CARDIA study, each additional hour of sleep was associated with lower risk of CAC.19 
Short sleep duration was also associated with greater CIMT,20 but only among men. In the Whitehall 
Study, participants with shorter sleep duration had higher rate of CVD mortality (HR 2.04, 95% CI 
1.20−3.49)119 compared to participants with  longer sleep duration.  
In addition to sleep duration, poor sleep quality either assessed through objective measurements of 
low sleep efficiency on actigraphy or subjectively through reports in insomnia has also been associated 
with adverse CVD outcomes. Poor sleep quality as assessed by decreased slow wave sleep (SWS) was 
associated with hypertension28 and obesity29 among adults. Poor sleep quality as assessed by low sleep 
efficiency and measured by actigraphy was also associated with higher blood pressure among healthy 
adolescents.30 Insomnia symptoms were associated with a higher rate of acute myocardial infarction in 
one large cohort study of men and women.26 Insomnia symptoms were also associated with higher risk of 
CVD120 and CHD mortality,121 only in men.  
One potential mechanistic link between sleep and CVD risk involves alteration of the function of the 
hypothalamic-pituitary-adrenal (HPA) axis with consequences for cortisol levels over the day. The 
secretion of cortisol, end product of the HPA axis, during the day exhibits a marked circadian pattern with 
a sharp increase within the first 30 minutes after awakening termed as the cortisol awakening response 
(CAR).53 The CAR is followed by a steep decline within the 2 hours after awakening (early decline) and 
then a slow decline over the rest of the day (late decline).52,54,122 Studies of the association between sleep 
characteristics and measures of HPA axis functioning have been inconsistent. In small experimental 
studies in young volunteers, both total and partial sleep deprivation were followed by increases in plasma 
or salivary evening cortisol.47-49 However, plasma cortisol level was lower the day following a night of 
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sleep deprivation in a study of 10 young healthy men,50 and the cortisol awakening response (CAR) was 
not affected in a study of imposed sleep disturbance in 13 young women.51 Observational studies 
investigating the associations between sleep duration and/or sleep quality (sleep efficiency or insomnia 
symptoms) and diurnal cortisol level have also been inconclusive. At least two epidemiological studies 
with large sample size found associations between sleep duration and/or sleep quality and cortisol. For 
example, in the Whitehall study, short sleep duration was associated with a more pronounced CAR and a 
less pronounced decline in cortisol,80 and poor sleep quality was associated with a less pronounced 
decline in cortisol.80,81 Other studies found no association between cortisol and sleep.79,93,115  
Prolonged sleep deprivation, which may result from intense psychological stress, has been thought to 
predict an allostatic overload involving the hypothalamic-pituitary-adrenal axis (HPA),and reducing 
parasympathetic tone, and increasing inflammatory markers.34 The HPA axis, one of the major 
neuroendocrine systems in response to stress, has also been linked to some health outcomes. For 
example, whereas subjects with higher levels of cognitive function keep healthy diurnal cortisol 
patterns,123 studies have found higher cortisol awakening response (CAR) in patients with current, 
remittent and at-risk depression compared to normal persons,105,106 and also blunted CAR in patients with 
depression compared to normal subjects.124 Flattened diurnal cortisol has also been associated with 
depression in patients with CHD125 and with cardiovascular and non-cardiovascular mortality.41,107 
Dysregulation of the HPA has also been linked to diabetes,126,127 and atherosclerosis.42   
It has also been suggested that short sleep duration is associated with adverse cardiometabolic 
outcomes when it is accompanied by poor sleep quality and insomnia symptoms.128 In support of this 
concept, the joint presence of insomnia and short sleep duration has been linked to higher risk of type-2 
diabetes,31 hypertension, 33 and mortality.129 The relationship between insomnia and cortisol has been 
investigated in a few small studies and findings were inconsistent. Whereas in two small case-control 
studies,130,131 insomnia was associated with higher evening cortisol level, in other studies insomnia was 
associated with lower awakening cortisol,91 or no association was found.132   
The inconsistencies in the association of sleep duration and sleep quality with diurnal cortisol may 
reflect differences in the samples, small sample sizes, measurement differences, or differences in 
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conceptualizing sleep exposures. Prior epidemiological studies have been limited by lack of objective 
measures of sleep duration and quality, lack of cortisol measures over the whole day, and lack of a 
comprehensive set of potential confounders. 
We hypothesized that participants with short sleep duration or poor sleep quality would have a less 
pronounced cortisol awakening response (CAR) and a shallower cortisol decline during the day than those 
with moderate duration of sleep. We further hypothesized that insomnia is a moderator in the association 
between sleep duration and cortisol, such that short sleep duration is associated with cortisol alterations 
only when insomnia is present. We conducted our study in a large population-based sample using 




The Multi-Ethnic Study of Atherosclerosis (MESA) is a longitudinal study designed to investigate risk 
factors for subclinical CVD and its progression to clinical CVD among middle-aged and older adults 
recruited at six field centers in the United States. In 2000-2002, MESA recruited 6814 men and women 
44-84 years old and free of clinically diagnosed CVD.133 At each of 5 exams, participants provided 
information on medical history, behavioral habits, and psychosocial factors, and anthropometric 
measures, blood pressure readings, and assessments of cardiovascular risk status were obtained. Cohort 
members were also invited to participate in ancillary studies; two of them were the MESA Stress Study 
and the Sleep Study that were concomitant with the MESA Exam 5 (2010-2012). The MESA Study was 
approved by the IRB at each of the field centers, and all participants gave written informed consent at 
each exam.  
The MESA Stress ancillary study enrolled 1,082 MESA participants at the New York, Los Angeles, and 
Baltimore field centers during Exam 5. MESA Stress involved two-day collection of salivary cortisol 
samples and a stress challenge test in a different day. At the three MESA Stress field centers, 1083 
subjects participated in the Sleep Study; of these 622 also participated in the Stress Study. Of the 622 
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participants who completed both the Stress and Sleep protocols, we excluded those participants with 
extreme values for sleep hours (< 3 hours or ≥ 9 hours). Our final sample comprised 600 participants. 
Collection of salivary cortisol samples 
Participants were instructed to collect eight salivary samples per day over 2 weekdays, resulting in a 
maximum of 16 samples per person. They were instructed to chew a cotton swab gently for 1-2 minutes 
and then place it in a numerated salivette previously provided. The first sample was taken upon 
awakening, the second sample 30 min later, the third sample one hour after breakfast, the fourth sample 
around 10 am, the fifth sample at noon, the sixth sample around 4 pm, the seventh sample around 6 pm 
(or before dinner if dinner occurred before 6 pm), and the eighth sample right before bed. Participants 
were provided with a digital clock to record the time of salivary sample collection, and they were asked to 
write down the times of sample collection for each sample on a daily questionnaire. 
Measurement of salivary cortisol 
Salivary samples were stored at −20°C until analysis. Before biochemical analysis, samples were 
thawed and centrifuged at 3000 rpm for three minutes to obtain clear saliva with low viscosity. Salivary 
cortisol level was determined using a commercially available chemiluminescence assay with high 
sensitivity (0.16 ng/mL) (IBL Hamburg, Germany). Intra- and inter-assay coefficients of variation for the 
essay are <8%. Cortisol was measured in nmol/L (nanomoles per liter). 
The MESA Sleep Study was the second ancillary study also conducted at Exam 5. All MESA 
participants except those reporting regular use of oral airways support devices, nocturnal oxygen or 
nightly continuous positive airway pressure were eligible to participate. The protocol included 7-day 
actigraphy (Actiwatch Spectrum, Philips Respironics) together with 1-night home polysomnography 
(PSG), a sleep diary, and a sleep questionnaire. Actigraphy is an objective method of assessing sleep-
wake parameters in natural settings. It contains a chip that senses the signals generated by movements 
of the wrist and translates them into “activity” counts, which are translated into voltage that are gathered 
continuously and stored into epochs of one minute. While wearing the actigraph, participants recorded on 
the sleep diary information on bed and wake times, sleep onset, naps, actigraphy removal, and other 
unusual events. Actigraphic data during 30-second epochs were scored as sleep or wake by Actiware- 
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Sleep version 5.59 analysis software (Mini Mitter Co., Inc.). Summary data for average weekly sleep 
duration and sleep efficiency were generated using a validated algorithm134. Intrascorer intraclass 
correlation coefficients for average sleep duration and sleep efficiency were 0.91 and 0.97. 
Outcome Variables  
The diurnal cortisol profile was determined by using up to 16 measures of cortisol per participant from 
the two-day salivary cortisol collection. Samples were collected between awake and 16 hours after 
awakening. Samples taken after 16 hours of awakening were excluded because cortisol starts to rise 
again after 16 hours of awakening. We used the self-reported first sample collection time as an 
approximation of the wakeup time in order to keep comparability with other analyses done with the same 
dataset. We assigned time equal 0 hours to the first sample as time since wakeup. The distribution of the 
difference between the wakeup time and the first sample time of the day is shown in Supplemental Table 
C-1. The derived cortisol variables were wakeup cortisol (cortisol awakening level), cortisol awakening 
response (CAR) and early decline slope and late decline slope (See Figure 3-1). Additionally, we used two 
summary measures of cortisol: area under the curve (AUC) for a 16-hour day, and the overall decline 
slope (wake-to-bed slope).  
Exposure Variables 
Objective measures of sleep duration and sleep quality were averaged across at least four weekdays and 
one weekend day of actigraphy. Sleep duration was defined as the average time the participant subject 
spent asleep between sleep onset (sleep start time) and morning wakening (sleep end time) while in bed 
after “lights off.” It was calculated by taking the sum of all time asleep across the recording and dividing 
by the total number of main sleep periods. Sleep duration was estimated as a continuous variable (range 
3 to <9 hours); in addition less than 6 hours was defined as “short sleep.” Other cut points for short 
sleep duration (5 and 7 hours) were also analyzed in sensitivity analyses. Sleep efficiency, an objective 
measure of sleep quality, was defined as the percentage of time in bed after “lights off” spent sleeping. It 
was calculated by taking the sum of all sleep time divided by the sum of all in bedtime during main sleep 
intervals across the recording and multiplied by 100 to obtain a percentage. Sleep efficiency was analyzed 
as a continuous variable; in addition less than 85% was defined as low sleep efficiency.   
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Insomnia, a subjective measure of sleep quality, was assessed based on self-report using the 
Women’s Health Initiative Insomnia Rating Scale (WHIIRS), a 5-item questionnaire: 1) “Having trouble 
falling asleep,” 2) “Waking up several times a night,” 3) “Waking up earlier than planned,” 4) “Having 
trouble getting back to sleep after waking up too early,” and 5) “How was your typical night’s sleep.” 
Participants were asked to rate how frequently they experienced those difficulties over the past four 
weeks. Each question was scored on a 5-point scale (from 0−4). The summary score ranged from 0 to 
20. A score of ≥ 9 is considered clinically significant insomnia. 135  
Covariates 
Age, sex, race/ethnicity, awakening time, income-wealth index were examined. Family income and wealth 
were assessed by self-report at Exam 5. A 9-point income-wealth index was created by summing 
responses from a 5-category family income measure and a 5-point family wealth measure.136 Smoking 
was assessed at Exam 5 by using the following categories: “never smoked”; “former smoker quit more 
than 1 year ago”; “former smoker quit less than 1 year ago”; “current smoker”; and “do not know.” 
These responses were categorized as never smoker; former smoker quit more than 1 year ago; and 
current smoker and former smoker quit less than 1 year ago, as one category, because the category of 
current smokers included a few participants. Alcohol consumption was assessed using the response to 
the following: “Do you presently drink alcoholic beverages?:” Yes/No. Body mass index (BMI) (kg/m2) 
was calculated as weight in kilograms divided by height in meters squared.  
Cynical hostility was measured at Exam 5 using an 8-item subscale of the full Cook-Medley Hostility 
Scale137 with higher scores indicating higher levels of cynical-hostility. Cynical-hostility was analyzed as 
tertiles. Depression was assessed at Exam 5 using the 20-item Center for Epidemiology Studies-
Depression (CES-D) scale138 with higher scores indicating higher levels of depressive symptoms. A CES-D 
score of ≥16 was defined as depression, consistent with mild-to-moderate depression in the 
population.139 Depression scores were entered in the models as a continuous variable. 
Other covariates included prevalent diabetes and hypertension as of Exam 5, and use of certain 
medications. We grouped medications used for sleep and/or mood (non−tricyclic antidepressants, 
tricyclic anti-depressants, norepinephrine-dopamine reuptake inhibitors, serotonin antagonists and 
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reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, 
anti-psychotic medications, and benzodiazepines); oral and inhaled steroids; and hormone replacement 
therapy (HRT) (estrogens, including vaginal creams; progestins; and premarin (conjugated estrogens)).  
The apnea/hypopnea index (AHI) was calculated based on data from the overnight PSG. Apnea was 
defined as complete or near complete cessation of airflow for ≥10 seconds, and hypopneas as at least 
30% below baseline breathing amplitude for ≥10 seconds. We included only apneas and hypopneas that 
were associated with ≥3% desaturation. The AHI was calculated as the total number of apneas and 
hypopneas per hour of sleep. It was included in the models as a continuous variable. 
Analysis  
A total of 1082 participants were enrolled in the MESA Stress Study 2, providing 2164 days of salivary 
cortisol data and 17312 samples. We excluded observations or participants as follows: First, we excluded 
6 days of data (48 samples) missing sampling times (since wakeup) for the entire day of data collection; 
second, we excluded days that were missing cortisol value for the entire day of data collection (24 days 
and 192 samples); third, we excluded individual samples with missing sampling times (since wakeup) or 
missing cortisol values (1040 samples). Fourth, we excluded samples with cortisol values over 100 nmol/L 
(113 samples) and samples with cortisol values of 0 nmol/L (4 samples). Fifth, we excluded participants 
with no measure of sleep duration because they did not participate in the Sleep Study (447 participants). 
Finally, we excluded participants who had slept ≤3 hours (11 participants) or >9 hours (11 participants) 
because these two groups had few participants < 2% in each group. Our final analytical sample included 
600 participants over 1198 days with 8985 samples. (Supplemental Figure C-1 illustrates these 
exclusions). In our final dataset, we found participants with abnormal wakeup times; 4 subjects (6 days) 
had a very early wakeup (before 3:00 am) and other 4 subjects (4 days) a very late wakeup (after 11:00 
am). We did not exclude these participants, but we did a sensitivity analysis and found no differences in 
including or not this group of participants. Most participants (88%) in our dataset collected at least 14 
salivary samples over two days (see   
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Supplemental Table C-2). Most participants collected at least 7 salivary samples per day (day 1: 92% and 
day 2: 89%) (Supplemental Table C-3).  
Associations of sleep measures with features of the daily cortisol curve before and after adjustment 
for covariates were examined using piecewise linear regression mixed models consistent with Ranjit 
(2009).140 We used a piecewise linear mixed model with two knots at 0.5 hours and at 2 hours after 
wake-up to capture the inflections of the diurnal cortisol profile Figure 3-1. The rational to select the two 
knots at 0.5 after wakeup as the first knot and 2 hours after wakeup as the second knot is because 
salivary cortisol samples were collected at 30 minutes and two hours after wakeup. Most participants had 
peak cortisol level at 0.5 hours (2nd sample) and then there is a steep decline between the 2nd and 3rd 
samples with the declining rate gradually leveling over the 3rd through the 8th samples (See Table 3-1 and 
Figure 3-2). The distribution of the salivary sample collection time (hours) of our data set is shown in 
*For instance, on day 1, only 2 participants provided one sample for the whole day whereas 399 





Supplemental Table C-4. The two knots produce a three-spline model. We computed the cortisol 
features of this sample by pooling all the data across all the day for the individual (up to 16 samples per 
participant). Using all cortisol samples in the model allows us to investigate associations of each exposure 
with the diurnal cortisol profile as a whole including the main features: wakeup, CAR, early decline and 
late decline. This approach as opposed to modeling each of the features separately and/or averaging the 
features computed for each day has more statistical efficiency. The cortisol features associated with the 
exposure are derived from the parameter estimates from the fixed effect in the model. We included the 
random slopes for only the first and third pieces of spline because when we included the second spline 
the models did not converge. The objective of our analysis was to identify differences by exposure in the 
cortisol curve. Cortisol values were log transformed (log (nmol/L)) to approximate it to a normal 
distribution, therefore, the exponentiated coefficients from the models were construed as percent 
differences. Positive percent differences in the wake-up cortisol indicate higher cortisol levels; positive 
percent differences in the CAR indicate a sharper rise in cortisol; and positive percent differences in the 
early and late decline indicate a flatter decline in cortisol. 
We computed several cortisol features. The cortisol awakening response (CAR) was calculated as the 
difference between the wake up cortisol levels and the levels at 30 minutes post-awakening. The early 
decline slope (between 30 minutes and 2 hours post-awakening) and the late decline slope (between 2 
hours post-awakening and bedtime) were calculated as the average hourly rate of decline for the given 
time period. The overall slope was calculated as the average hourly rate of decline from wakeup to 
bedtime (excluding the 2nd sample when calculated). AUC was defined as the area under the cortisol daily 
curve standardized by 16 hours. 
We examined the shape of the cortisol profile over the course of the day using locally estimated 
scatter plot smoothing (LOESS)141 following previous studies,136 for the whole population and by gender 
(Figure 3-2), and also stratified by sleep duration (Supplemental Figure C-2) and sleep quality 
(Supplemental Figure C-3) as well as by race/ethnicity and age (Supplemental Figure C-4). 
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We examined participant characteristics and cortisol measures by categories of sleep duration and 
sleep efficiency. The statistical significance of differences in cortisol variables and covariates by sleep 
duration and sleep efficiency category was evaluated by ANOVA for continuous variables or Kruskall 
Wallis when variables had a skewed distribution and chi-square tests for categorical variables.  
All covariates were centered with respect to the grand mean when included in the models. Centering 
supports interpretation of the model intercept for an average population.142 All models were adjusted for 
time of wake-up, first vs. second day of salivary collection, age, gender, race/ethnicity, and income-
wealth index. 
Analyses of sleep duration and sleep quality were performed using both categorical and continuous 
measures. In the analysis of sleep duration, model 1 was adjusted for first vs. second day of salivary 
collection, wake-up time, gender, age, race/ethnicity, and income-wealth index. Model 2 was adjusted for 
covariates included in model 1 plus BMI, smoking, alcohol consumption, medications, and AHI. Model 3 
included covariates in model 2 plus hypertension, diabetes, and depression. Model 4 (fully adjusted 
model) for sleep duration included covariates in model 3 plus sleep efficiency and for sleep efficiency as 
the predictor model 4 included sleep duration as a covariate. All covariates included in the models were 
entered as main effect and as interacting with pieces of the daily curve. 
We also calculated the wake-to-bed slope in cortisol level to analyze the associations of sleep 
duration and sleep quality with a summary measure of cortisol decline over the day. This summary 
measure, reported in prior studies,143  is the slope of the decline of cortisol between wake-up and 
bedtime. Consistent with previous study, we estimated the wake-to-bed slope within the mixed model 
(excluding the 30 minute sample), and used the same covariates in the models as described above. In 
addition, we investigated the cortisol area under the curve (AUC) for a 16- hour day, a second summary 
measure of the daily cortisol profile, and estimated it within the mixed model. 
We explored effect modification using stratified analyses to study the role of insomnia in the 
association of sleep duration with alterations in the diurnal cortisol level. A test for interaction between 
insomnia symptoms and sleep duration was used to test whether the association of sleep duration with 
cortisol differed between subjects with and without insomnia. We first examined whether the insomnia 
39 
 
covariate was statistically significant with P <.2, and then we included in the model the main effect, two-
way interactions with the three spline pieces, and three-way interactions (insomnia, sleep duration, each 
of the three spline pieces). 
Test of interaction between gender, age (54 to <68, 68 to < 75 and 75 years old or more) and 
race/ethnicity (whites, African Americans and Hispanics) and sleep duration were also examined including 
three way interaction terms for the slopes.  
We performed secondary analyses in which we restricted our sample to participants younger than 75 
years, to those without depression, to nonusers of oral/inhaled steroids, to nonusers of antidepressants, 
and to participants with an apnea hypopnea index of less than 15 (without moderate or severe apnea). 
We also investigated alternative cut points of both sleep duration and sleep efficiency. 
Results 
Our overall sample consisted of 316 (53%) women and 284 (47%) men from three different race/ethnic 
backgrounds, Hispanic (40%), African-American (32%), and white (28%), and the mean age was 69.2 
(S.D. 9) years. Table 3-1 shows summary characteristics for the 600 participants included in the analyses 
by sleep duration and sleep efficiency. Participants were categorized as “short” sleepers (<6 hours) 
(n=202) and “longer” sleepers (≥6 to <9 hours) (n=398), and as “low” sleep efficiency (<85%) (n=60) 
and “higher” sleep efficiency (≥85%) (n=540). The median (interquartiles: Q1−Q3) evening cortisol (at 
bedtime) was higher among short sleepers (3.6 nmol/L, 2.1−7.0) compared to longer sleepers (3.3 
nmol/L, 1.9−5.3; P=.03). The normal median for the evening cortisol in this assay is approximately 2.0 
nmol/L (10th percentile=0.1− 90th percentile=6.0). Characteristics of the study participants by insomnia 
symptoms are also shown in Table 3-2.  Supplemental Table C-5 shows selected characteristics of 
participant demographics by cortisol data collection.  
Sleep Duration  
Characteristics of participants by mean sleep duration (hours) are shown in Supplemental Table C-6. 
Men, African-Americans, low income participants, and participants who were obese, diabetic, used 
inhaled steroids, or had low sleep efficiency had lower average sleep duration than their counterparts.  
Table 3-3, first column, shows percent differences and 95% confidence intervals (CI) between short 
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and longer sleep duration in features of the diurnal cortisol profile, and the wake-to-bed slope and AUC. 
Short sleep duration was associated with less pronounced late decline in all models (model 4, 2.2% 
difference in slope; 95% CI 0.8−3.7; P ≤.01) and with less pronounced wake-to-bed slope in all models 
(model 4, 2.2% difference; 95% CI 1.0−3.4; P ≤.001). Short sleep duration was not associated with 
AUC. Consistent patterns were observed when sleep duration was investigated as a continuous variable 
(Supplemental Table C-7, first column).  
Sleep efficiency  
Sleep efficiency ranged from 71.62% to 96.98%. Table 3-1 shows that participants with low sleep 
efficiency had lower levels of cortisol at awakening (p-value =0.02) and 30 minutes after (p-value =0.01) 
compared to those with higher sleep efficiency, but there was no difference in the evening cortisol 
between the two groups. 
Low sleep efficiency was associated with less pronounced early decline in all models (model 4, 
29.0% difference in slope; 95% CI 4.1−59.7; P ≤.05) (Table 3-3, second column). Sleep efficiency was 
not associated with the wake-to-bed slope or AUC. Consistent patterns were observed when sleep 
efficiency was investigated as a continuous variable (Supplemental Table C-7, second column).  
Insomnia  
Table 3-2 shows summary characteristics for the 591 participants who had insomnia data. In this analytic 
sample, 209 participants (35%) reported insomnia symptoms. This group was more likely to include 
women, to be in the lowest categories of the income-wealth index, and to report higher scores of 
depression symptoms and hostility compared to those without insomnia symptoms.   
Table 3-4 shows the associations between insomnia and cortisol levels in the full sample and 
stratified by short vs. longer sleep duration. Overall, insomnia was associated with less pronounced CAR 
in models 1, 2, and 4 (model 4, −16.1% difference; 95% CI −34.6 to −0.1; P <.05) compared to those 
without insomnia (Table 3-4, first column). In the subsample of short sleepers, insomnia was associated 
with less pronounced CAR compared to those without insomnia in all models (model 4, −37.7% 
difference; 95% CI −79.4 to −5.7; P <.05) (Table 3-4, second column). In the subsample of longer 
sleepers, insomnia was associated with a more pronounced late decline in cortisol and more pronounced 
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wake-to-bed slope compared to those without insomnia in all models (Table 3-4, third column).     
We also compared the association between sleep duration and salivary cortisol in participants with 
and without insomnia. In the group with insomnia (Table 3-5, first column), short sleep duration was 
associated with less pronounced CAR in models 3 and 4 and with less pronounced late decline in cortisol 
in all models (model 4, 3.6% difference in slope; 95% CI 1.2−6.0; P ≤.01) compared to longer sleep 
duration. This was not observed in the group without insomnia (Table 3-5, second column). Both the 
groups with and without insomnia showed less steepness in the wake-to-bed cortisol slope in those with 
short vs. longer sleep duration (Table 3-5). The statistical test for interaction between insomnia and sleep 
duration was of marginal significance (P for interaction = 0.1). 
Secondary analyses  
Participants with depression represented 17% (N=600) of our sample. Only the second sample of salivary 
cortisol (taken 30 minutes after awake) was different among those who had CES-D ≥16 (median=18.9 
nmol/L, Q1−Q3=12.8−28.9) compared to those with CES-D <16 (median=22.3 nmol/L, 
Q1−Q3=15.5−31.5). Salivary cortisol levels did not differ between participants with depression taking 
antidepressants compared to those who were not, or between those with hypertension or diabetes 
compared to those without hypertension or diabetes.  
Results of analyses restricted to participants younger than 75 years old, those without depression, 
non-users of antidepressants, non-users of oral/inhaled steroids, and participants without moderate sleep 
apnea were not materially different from the unrestricted analyses. Our results did not differ from the 
unrestricted sample when we excluded participants with sleep duration between 8 and 9 hours (n=53)  
(Supplemental Table C-8). Analyses using 7 hours (n=399) as the cut point for short vs. longer sleep 
duration did not differ materially from analyses using 6 hours as the cut point but analyses using 5 hours 
(n for short sleepers =69) as the cut point differed in that point estimates were lower than those using 6 
hours as the cut point and did not reach statistical significance for both the whole and restricted (<8 
hour) samples ( Supplemental Table C-9). For sleep efficiency, very few participants would have been 
categorized as having “low sleep efficiency” for cut points lower than 85%. Finally, in this analysis we 
could not demonstrate an interaction effect of gender, age or race/ethnicity on the relationship between 
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short sleep duration and/or poor sleep quality and diurnal cortisol. 
Discussion 
In this population-based study of adults, using multiple measures of salivary cortisol and objective 
in-home sleep data, we found that sleep duration and sleep quality were associated with alterations of 
the diurnal cortisol patterns. Notably, short sleep duration was associated with less pronounced late 
decline in cortisol and less pronounced wake-to-bed slope. These associations remained significant after 
adjustment for sleep apnea, sleep efficiency and other covariates and were robust to various sensitivity 
analyses. Low sleep efficiency was also associated with less pronounced early cortisol decline although 
was not confirmed in analyses of the slope of wake-to-bed cortisol. The association also remained 
significant after adjustment for sleep apnea, sleep duration and other covariates. In stratified analyses, 
we found some evidence that associations of sleep duration with diurnal salivary cortisol were stronger 
among study participants who also reported insomnia symptoms than among those who did not. The test 
for interaction was of marginal statistical significance. We did not find associations of sleep characteristics 
with AUC, suggesting that this summary measure may be less sensitive to sleep-associated alterations in 
the diurnal cortisol profile than specific components (features of the cortisol) examined using the 
piecewise linear mixed models.  
Several observational studies have described alterations of the diurnal cortisol profile associated with 
psychological and psychosocial factors as well as with health outcomes. Although the findings are mixed, 
a consistent pattern that seems to be emerging is the association of adverse risk profiles (or disease 
outcomes) with a flatter decline in cortisol over the day (and consequent higher bedtime levels). For 
example, a flattened diurnal pattern has been associated with atherosclerosis in the CARDIA study;144 and 
a flattened slope, due to lower morning cortisol, was associated with home-related stress.145 Findings for 
the CAR, however, have been more mixed. For instance, higher CAR has been found in patients with 
depression compared to non-depressed persons,105,106 but also a blunted CAR has been found in patients 
with depression compared to normal subjects.124 A large CAR and flattened diurnal decline was found to 
be associated with work-related stress;146 and a flattened CAR was also associated with burnout.147 Lower 
cortisol levels at wake-up and less pronounced early decline in cortisol associated with low-socioeconomic 
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status,136 low CAR levels associated with diabetes126 and low levels of awakening cortisol and a less 
pronounced decline in cortisol associated with markers of obesity127 have been found in the MESA Study.  
We consistently found a flatter decline in cortisol associated with short sleep duration that was 
present in the overall population, those with and without insomnia, and after controlling for sleep 
efficiency, suggesting that short sleep duration independent of insomnia and poor sleep is associated with 
evening cortisol elevation. We observed associations with the late decline and the total wake to bed 
slope. The flatter late decline in cortisol seen in our population with short sleep duration could be 
attributable to either low awaking cortisol level or high evening cortisol level. However, we found no 
association of short sleep duration with awakening cortisol levels suggesting that changes in wake-up 
level did not account for these slope differences. The flattened evening cortisol associated with sleep 
duration found in our study could also be explained by the effect of age, but our analyses adjusted for 
age and we found same associations after restricting our sample to participants with ≤75 years old. It 
has been suggested that older people keep more a “typical” diurnal cortisol profile than younger 
people.148    
Only a few population-based studies have examined associations of sleep with the daily cortisol 
profile. The Whitehall II Study,80 a large cohort of London-based civil servants, with 2751 participants 
collected up to six salivary cortisol samples on a weekday, but sleep duration and sleep quality were self-
reported. The study found that short sleep duration was associated with an increased CAR and a 
shallower slope in cortisol, and that sleep disturbance was associated with a shallower slope in cortisol. 
Our study differs from the Whitehall Study in having objective data of sleep including sleep duration, 
sleep efficiency and apnea, and up to 16 salivary samples per participant. Our findings are consistent 
with the Whitehall findings in that shorter sleep duration and poorer sleep efficiency were associated with 
a less pronounced decline in cortisol.  
A second relevant study is a Danish study81 (n~4,060) with salivary samples at three time points in a 
day and self-reported sleep duration and quality. This study did not find associations between sleep 
duration and cortisol but did find associations between sleep problems and lower morning cortisol. In a 
follow-up study with 387 participants, with one additional salivary sample (at awakening), the study also 
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found associations between poor sleep quality and less pronounced decline in cortisol. Our has analysis 
that was based on a larger number of salivary samples over two days, objective measures of sleep 
duration and quality, and a more heterogeneous population.  
Other observational studies using different methodology from our study found no associations. A 
study from China115 examined 96 study participants using 3-day actigraphy with 3 days of only awakening 
salivary cortisol and found that salivary awakening cortisol was not associated with sleep duration and 
sleep efficiency. This study was unable to characterize the diurnal cortisol profile. In the Osteoporotic 
Fractures in Men (MrOs) Study,79 actigraphy-based sleep duration and 24-hour free urinary cortisol were 
measured. No association between sleep duration and urinary cortisol was found. Urinary cortisol has the 
advantage of assessing nighttime cortisol levels, but urinary free cortisol represents a small fraction 
(2−3%) of the total cortisol released by the adrenal cortex.149 It is a summary measure and it does not 
characterize the diurnal cortisol profile.  
Prior studies have not reported associations of sleep duration with cortisol stratified by insomnia 
symptoms. When we compared the association between sleep duration and salivary cortisol in 
participants with and without insomnia we found that associations of sleep duration with cortisol were 
stronger in those who reported insomnia. There was some evidence that in the group with insomnia 
shorter sleep duration was associated with a less pronounced CAR and a less pronounced late decline in 
cortisol compared to longer sleep duration. However, interactions between insomnia and sleep duration 
were not statistically significant in our sample. The stronger association of sleep duration with cortisol in 
those who reported insomnia could be related with the findings of the joint effect of short sleep duration 
and insomnia on hypertension,33 type-2 diabetes,31 and mortality129 reported by Vgontzas et. al.  
We also found that insomnia was associated with a reduced CAR in the full sample and this 
association was driven by the short sleepers whereas insomnia was associated with a more pronounced 
decline in the longer sleepers (persons who slept ≥6 hours). This finding is in part in accordance with a 
study in which higher indexes of sleep disturbance, in subjects with primary insomnia, were associated 
with lower awakening cortisol, and with non-significant lower CAR.91 But, it is not in agreement with other 
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studies in which insomnia was associated with elevation of the evening cortisol,130,131 or no association 
was found.132 These mixed findings suggest that more studies need to be done in this area.  
Our study has several limitations. First, our data are cross-sectional and therefore we cannot rule 
out bidirectional causality.96,150 We approached the analysis a priori from a causal framework in which 
sleep duration and quality were considered as the independent variables and HPA axis measures were 
taken as the dependent variables but cannot determine the direction of causality (e.g. we cannot be sure 
that elevation of cortisol later in the day prevents a normal and/or good sleep vs. the other way around.)  
Second, both sleep and cortisol data were collected from each subject at a single point in time, and intra-
individual variability over time for both sleep and cortisol profiles was not captured. However, sleep 
stability has been evaluated in at least two studies. In the CARDIA Study, investigators determined that 
even though night-to-night sleep is variable, sleep parameters (duration, efficiency, and latency) 
measured by actigraphy and supplemented by a log diary tend to be relatively stable from year to year in 
middle age adults.151 A study among middle-aged Chinese adults reported similar findings over 3-year 
period.115 The daily cortisol profile also varies from day to day. The use of two consecutive days is an 
advance over single day studies. Data from MESA suggest that the long term stability over 6 years is 
moderate (intraclass correlation 0.25 for the early decline and 0.42 for the late decline).152 Variability in 
both sleep and cortisol over time may have resulted in underestimates of the true associations. Third, the 
definition of insomnia is dependent on the subjective experience of disturbed sleep,153 but most 
importantly is a common clinically recognized entity that may represent several subphenotypes that need 
to be identified. Fourth, power to assess associations with poor sleep efficiency was limited because only 
10% of our participants sample had low (<85%) sleep efficiency.   
A strength of our study is the availability of high quality data for a variety of covariates including 
sleep apnea. Except for one study,79 the studies mentioned above did not adjust for this variable. A 
second strength is that we had objective sleep data derived from 7-day actigraphy and 1-night PSG. A 
third strength is that we had up to 16 salivary samples over two days, allowing us to model the diurnal 
cortisol profile.  A fourth strength is our analytic approach. We used piecewise linear mixed models with 
splines to account for the non-linear diurnal profile, for the correlations of the repeated cortisol measures 
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within individual, for varying number of observations, and for differences in the timing of data collection. 
A fifth strength is our large diverse population based sample. 
In summary, our results provide evidence of associations of shorter sleep duration and worse sleep 
quality with alterations in features of the diurnal cortisol profile. These differences in the diurnal cortisol 
profile may contribute to the increased risk of cardiovascular disease, cardiovascular risk factors and 





Table 3-1 Characteristics of participants (n= 600) by sleep duration and sleep efficiency, MESA Study 
(2010-2012) 
 Sleep Duration (hours) Sleep Efficiency (%) 
 
< 6 h 
(n = 202) 
≥ 6 h 
(n = 398) 
p-value 
< 85% 
(n = 60) 
≥ 85% 
(n = 540) 
p-value 
 N (%) or Mean ± SD N (%) or Mean ± SD 
Demographics 
   
   
Age (years)  68.6 ± 9.0 69.4 ± 9.0 0.3 70.3 ± 7.4 69.0 ± 9.2 0.2 
Male 106 (53) 178 (45) 0.07 35 (58) 249 (46) 0.07 
Race/ethnicity    <.001   0.2 
   White 36 (18) 130 (33)  11 (18) 155 (29)  
   Black 92 (45) 99 (25)  24 (40) 167 (31)  
   Hispanic 74 (37) 169 (42)  25 (42) 218 (40)  
Income-Wealth Index     0.1   0.03 
   0 − 1 33 (18) 41 (12)  12 (21) 62 (13)  
   2 − 3 41 (22) 83 (24)  5 (9) 119 (25)  
   4 − 6 80 (43) 142 (41)  28 (49) 194 (41)  
   7 − 8 33 (18) 83 (24)  12 (21) 104 (22)  
Married 98 (50) 230 (59) 0.05 35 (59) 293 (56) 0.6 
Lifestyle characteristics      
Body Mass Index(1)  kg/m2   <.001   0.2 
   Normal 30 (15) 88 (22)  8 (13) 110 (20)  
   Obesity Grade 1 75 (37) 163 (41)  24 (40) 214 (40)  
   Obesity Grade 2 82 (41) 139 (35)  23 (38) 198 (37)  
   Obesity Grade 3 15 (7) 8 (2)  5 (8) 18 (3)  
Smoking status     0.1   0.3 
   Current 23 (11) 25 (6)  4 (7) 44 (8)  
   Former and quit > 1 year 
ago  
66 (33) 156 (39)  28 (47) 194 (36)  
   Never 112 (56) 215 (54)  28 (47) 299 (56)  
Alcohol consumption 
(Yes/No)   
75 (37) 164 (41) 0.4 23 (38) 216 (40) 0.8 
Hypertension  127 (63) 231 (58) 0.3 37 (62) 321 (59) 0.7 
Diabetes  83 (41) 165 (42) 0.9 30 (50) 218 (41) 0.2 
Depression CESD >16  39 (20) 58 (15) 0.1 11 (19) 86 (16) 0.7 
Hostility (tertiles)    0.2   0.9 
   Highest 58 (29) 95 (25)  16 (27) 137 (26)  
   Second 87 (44) 151 (40)  23 (39) 215 (41)  
   Lowest 55 (28) 133 (35)  20 (34) 168 (32)  
Oral Steroids users   3 (2) 5 (1) 0.8 2 (3) 6 (1) 0.2 
Inhaled Steroids users  11 (6) 4 (1) <.001 2 (3) 13 (2) 0.7 
Antihypertensive users   122 (60) 218 (55) 0.2 35 (58) 305 (57) 0.8 
HRT(2) users   4 (2) 14 (4) 0.3 0 (0) 18 (3) 0.2 
Antidepressant users  17 (8) 49 (12) 0.2 6 (10) 60 (11) 0.8 
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Sleep Variables       
Insomnia told by a  doctor   14 (7) 27 (7) 0.9 4 (7) 37 (7) 0.9 
Insomnia symptom (3) 75 (38) 134 (34) 0.4 24 (41) 185 (35) 0.4 
       
Sleep efficiency (%)       
   Low (<85%) 32 (16) 28 (7) <..001 NA NA  
Sleep Duration         
   Short (<6 hours) NA NA  32 (53) 170 (32) <.001 
Apnea and hypopnea         
   Index(4) (AHI) ≥ 15 109 (63) 214 (58) 0.3 39 (72) 284 (52) <0.05 
Cortisol Measures       
Median (Q1-Q3), 
   (mmol/L) 
      















































































































*either chi-square or t-test/ANOVA or  Kruskall Wallis test for variables non-normally distributed       
 
(1) Body mass index, WHO categories: 
a. Normal: 18.5 – 24.9 
b. Obesity I : 30.0-34.9 
c. Obesity II: 35.0-39.9 
d. Obesity III: ≥ 40.0     
(2) HRT = Hormone Replacement Therapy 
(3) assessed by WHIIRS score ≥9 = insomnia  










   
  
Yes No Total P-value 
  
N % N % N % 
 
  
209 35.4 382 64.6 591 100.0   
Demographics 
       Age group 
      
0.6 
 
54 − 64 75 35.9 130 34.0 205 34.7 
 
 
65−74 68 32.5 139 36.4 207 35.0 
 
 
 >75 66 31.6 113 29.6 179 30.3 
 Male 
 
79 37.8 200 52.4 279 47.2 <.001 
Race/ethnicity  
      
0.3 
 
White 50 23.9 113 29.6 163 27.6 
 
 
Black 68 32.5 120 31.4 188 31.8 
 
 
Hispanic 91 43.5 149 39.0 240 40.6 
 Income−wealth index 
      
<0.01 
 
0−1 32 15.3 41 10.7 73 12.4 
 
 
2−3 51 24.4 71 18.6 122 20.6 
 
 
4−6 75 35.9 144 37.7 219 37.1 
 
 
7−8 26 12.4 88 23.0 114 19.3 
 Married 99 47.4 225 58.9 324 54.8 0.02 
Lifestyle characteristics 
       Body mass index 
      
0.3 
 
Normal 43 20.6 74 19.4 117 19.8 
 
 
Obesity grade 1 88 42.1 146 38.2 234 39.6 
 
 
Obesity grade 2 67 32.1 150 39.3 217 36.7 
 
 
Obesity grade 3 11 5.3 12 3.1 23 3.9 




   
0.8 
 
Current 16 7.7 30 7.9 46 7.8 
 
 
Former (quit >1 year ago) 81 38.8 138 36.1 219 37.1 
 
 
Never 111 53.1 212 55.5 323 54.7 
 Alcohol user  74 35.4 160 41.9 234 39.6 0.1 
Hypertension  124 59.3 230 60.2 354 59.9 0.8 
Diabetes  89 42.6 156 40.8 245 41.5 0.8 
Depression CESD >16  51 24.4 44 11.5 95 16.1 <.0001 
Hostility (tertiles)  
      
0.03 
 
Highest 60 28.7 90 23.6 150 25.4 
 
 
Middle 85 40.7 149 39.0 234 39.6 
 
 
Lowest 50 23.9 136 35.6 186 31.5 
 Oral steroids user  2 1.0 6 1.6 8 1.4 0.5 
Inhaled steroids user 4 1.9 1 0.3 5 0.8 0.5 
Antihypertensive user   121 57.9 214 56.0 335 56.7 0.7 
HRT user   5 2.4 13 3.4 18 3.0 0.5 
Antidepressant user  24 11.5 42 11.0 66 11.2 0.9 
         Sleep variables 
       Insomnia told by a  doctor(1)   29 13.9 12 3.1 41 6.9 <.0001 
Sleep duration < 6 hours 75 35.9 123 32.2 198 33.5 0.4 
Sleep efficiency % <85% 24 11.5 35 9.2 59 10.0 0.4 
Apnea/hypopnea index  ≥ 15  111 53.1 77 20.2 188 31.8 0.8 




Mean SD Mean SD Mean SD p−value 
Wakeup after sleep onset(2) (min) 43.7 17.8 40.3 15.5 41.5 16.5 0.02 
Sleep latency(3) (min) 4.1 2.4 4.4 2.7 4.2 2.6 0.1 
         Cortisol measures Median Q1−Q3 Median Q1−Q3 Median Q1−Q3 p−value 
Wake−up 16.3 11.0−23.3 16.0 10.8−22.6 16.1  10.9−22.7  >0.1 
30 minutes later 21.3 13.6−29.6 22.3 15.4−32.0 22  14.7−30.9  0.08 
1 hour after breakfast 11.8 8.5−16.5 11.3 8.0−16.3 11.4  8.2−16.5  >0.1 
~10:00 am 8.9 6.6−12.4 8.9 6.5−12.9 8.9  6.5−12.6  >0.1 
~ Noon 7.5 5.2−10.6 7.6 5.2−10.8 7.5  5.2−10.7  >0.1 
~ 16:00 (4:00 pm) 5.3 3.5−8.5 5.8 3.7−8.2 5.5  3.7−8.3  >0.1 
~ 18:00 (6:00 pm) 4.0 2.6−6.5 4.3 2.7−6.6 4.1  2.6−6.6  >0.1 
Bedtime 3.3 1.9−6.1 3.3 2.0−5.7 3.3  2.0−5.8  >0.1 
*either chi-square or t-test/ANOVA or  Kruskall Wallis test for variables non-normally distributed       
 
(1) insomnia disorder  
(2) WASO, wake time after sleep onset, an indicator of sleep fragmentation 




Table 3-3.Percent differences (95% confidence intervals) in features of the daily cortisol (wake-up, CAR, 
early decline and late decline) and summary measures of cortisol (wake-to-bed slope and AUC) 
associated with sleep duration and sleep efficiency 
 Sleep Durationa Sleep Efficiencyb 
 _________________________________ _________________________________ 
 (< 6 hr vs.≥ 6 to < 9 hr) (< 85% vs.≥ 85%) 
Percent difference in wake-up     
Model 1c −11.93 (−30.9, 4.3) −33.73 (−81.5, 1.5) 
Model 2d −12.57 (−34.4, 5.7) −37.91 (−93.8, 1.8) 
Model 3e −10.95 (−33.0, 7.4) −39.44 (−97.4, 1.5) 
Model 4f −8.20 (−29.1, 9.3) −36.98 (−93.5, 3.0) 
Percent difference in cortisol awakening response (CAR)   
Model 1c −8.70 (−25.2, 5.6) −2.00 (−27.6, 18.47) 
Model 2d −8.16 (−26.6, 7.6) 0.29 (−21.9, 28.7) 
Model 3e −9.40 (−28.5, 6.9) 0.09 (−22.2, 28.8) 
Model 4f −9.57 (−27.9, 6.1) 2.35 (−20.1, 31.0) 
Percent difference in early decline   
Model 1c 6.34 (−5.0, 19.0) 22.12 (0.7, 48.2)§ 
Model 2d 6.02 (−6.4, 20.0) 25.97 (2.8, 54.4)§ 
Model 3e 5.28 (−7.3, 19.6) 27.65 (3.7, 57.2)§ 
Model 4f 2.35 (−9.7, 15.9) 28.96 (4.1, 59.7)§ 
Percent difference in late decline   
Model 1c 1.86 (0.6, 3.1)* −0.85 (−2.7, 1.0) 
Model 2d 2.02 (0.7, 3.4)* −1.05 (−3.2, 1.0) 
Model 3e 2.05 (0.7, 3.5)* −0.98 (−3.1, 1.1) 
Model 4f 2.23 (0.8, 3.7)* −1.84 (−4.2, 0.4) 
Summary measures of cortisol 
Percent difference in wake-to-bed slope  
Model 1c 2.15 (1.1, 3.2)*** 0.45 (−1.2, 2.1) 
Model 2d 2.33 (1.2, 3.5)*** 0.59 (−1.2, 2.4) 
Model 3e 2.27 (1.1, 3.5)*** 0.75 (−1.0, 2. 6) 
Model 4f 2.22 (1.0, 3.4)** 0.06 (−1.8, 1.9) 
Percent difference in area under the curve (AUC)  
Model 1c   0.34 (−10.6, 12.7) −8.97 (−32.6, 10.5) 
Model 2d   0.77 (−11.4, 14.9) −6.56 (−32.8, 14.5) 
Model 3e   0.28 (−12.1, 14.5) −5.51 (−32.2, 15.8) 
Model 4f −0.15 (14.6, 12.5) −5.28 (−32.8, 16.6) 
§<0.05;   *≤0.01;   **≤0.001 ;   ***≤0.0001 
 
a  Sleep duration was estimated as dichotomized (short sleep duration (3 to < 6 hours) ) vs. longer (reference,  ≥ 6 hours to <  
9hours) 
b Sleep efficiency was estimated as dichotomized (low sleep efficiency (< 85%) ) vs. high (reference,  ≥ 85%)  
Models: 
c Model 1 : Model adjusted for day of salivary collection, time of wake-up, gender, age, race/ethnicity, and income-wealth index    
d Model 2 : Model 1 + body mass index, smoking, alcohol consumption, medications (oral and inhaled   steroids, hormone 
replacement therapy and antidepressants) and apnea/hypopnea index (AHI) 
e Model 3 : Model 2 + hypertension, diabetes, and depression 






Table 3-4. Percent differences (95% C.I.) in features of the daily cortisol and summary measures of 
cortisol associated with insomnia and stratified by short and longer sleepers 
 Insomniaa  vs. non-insomnia 
 Overall sample  Short Sleepersb   Longer Sleepersb 
 (3 h to < 9 h) < 6 hours ≥ 6 hours 
Percent difference in wake-up  
Model 1c 8.28 (−5.9, 24.7) 5.43 (−17.5, 34.8) 11.17 (−6.6, 32.3) 
Model 2d 6.40 (−8.7, 24.0) 9.40 (−17.5, 45.1) 7.10 (−10.7, 28.5) 
Model 3e 5.70 (−9.5, 23.5) 7.63 (−19.4, 43.8) 7.85 (−10.1, 29.3) 
Model 4f 6.97 (−8.6, 25.2) 10.86 (−16.9, 47.9) 8.18 (−10.0, 30.0) 
Percent difference in cortisol awakening response (CAR)  
Model 1c −18.73 (−36.1, −3.5)* −38.86 (−77.5, −8.6)* −8.30 (−27.2, 7.8) 
Model 2d −16.43  (−35.0, −0.4)§ −33.40 (−76.17, −1.0)§ −7.12 (−27.2, 9.8) 
Model 3e −15.90 (−34.8, 0.3) −36.53 (−80.5, −3.3)§ −5.90 (−25.2, 10.4) 
Model 4f −16.11 (−34.6, −0.1)§ −37.74 (−79.4, −5.7)§ −5.90 (−25.4, 10.6) 
Percent difference in early decline  
Model 1c 11.44 (0.7, 23.3)§ 15.85 (−4.6, 40.7) 9.75 (−2.3, 23.3) 
Model 2d 9.87 (−1.17, 22.2) 9.90 (−11.5, 36.4) 9.76 (−2.7, 23.8) 
Model 3e 8.65 (−2.7, 21.3) 9.31 (−12.5, 36.5) 8.80 (−4.1, 21.8) 
Model 4f 7.52 (-3.5, 19.8) 6.12 (-13.9, 30.9) 7.80 (−4.3, 21.5) 
Percent difference in late decline  
Model 1c −1.05 (−2.3, 0.2) 0.22 (−1.9, 2.4) −2.02 (−3.4, −0.7)* 
Model 2d −1.06 (−2.4, 0.2) 0.35 (−2.0, 2.7) −2.01 (−3.5, −0.7)* 
Model 3e −1.10 (−2.5, 0.2) 0.53 (−1.8, 2.9) −2.19 (−3.7, −0.7)* 
Model 4f −1.09 (−2.4, 0.2) 0.91 (−1.4, 3.3) −2.27 (−3.7, −0.8)* 
Summary measures 
Percent difference in wake-to-bed slope   
Model 1c  −0.60 (−1.6, 0.4)   0.17 (−1.7, 2.1) −1.20 (−2.5, −0.1)§ 
Model 2d −0.67 (−1.8, 0.4) −0.07 (−2.2, 2.0) −1.20 (−2.3, −0.1)§ 
Model 3e −0. 78 (−1.9, 0.3)   0.07 (−2.0, 2.2) −1.38 (−2.5, −0.3)* 
Model 4f −0.86  (−2.0, 0.3)   0.14 (−2.0, 2.3) −1.52 (−2.6, −0.4)* 
Percent difference in area under the curve (AUC)   
Model 1c −0.38 (−11.4, 9.6) −5.45 (−30.2, 14.6) 3.40 (−8.0, 16.2) 
Model 2d −2.26 (−14.4, 8.6) −4.31 (−30.9, 16.9) 0.47 (−11.1, 13.6) 
Model 3e −4.43 (−17.3, 7.0) −8.07 (−35.7, 13.9) −0.60 (−14.3, 11.5) 
Model 4f −4.66 (−17.7, 6.9) −7.77 (−35.5, 14.3) −1.17 (−15.2, 11.2) 
§  <0.05    *0≤0.01     
a  Insomnia symptoms WHIIRS (insomnia (score ≥ 9) vs. non-insomnia (reference, score < 9)) 
b Sleep duration was estimated as dichotomized (short sleep duration (3 to < 6 hours) ) vs. longer (reference,  ≥ 6 hours to < 9 
hours) 
c Model 1 : Model adjusted for day of salivary collection, time of wake-up, gender, age, race/ethnicity and income-wealth index   
d Model 2 : Model 1 + body mass index, smoking, alcohol consumption, and medications (oral and inhaled steroids, hormone 
replacement therapy and antidepressants), and apneas and hypopneas index (ahi) 
e Model 3 : Model 2 + hypertension, diabetes,  and depression 





Table 3-5. Percent differences (95% confidence intervals) in features of the daily cortisol and summary 
measures of cortisol associated with sleep duration specified as dichotomized and continuous stratified by 
insomnia symptoms 
 Sleep Durationb (dichotomized) Sleep Durationb (continuous) 
  (reference, ≥ 6 hours of sleep)  (1 hour less of sleep) 
 ____________________________________ ___________________________________ 
 With Insomnia Without Insomnia With Insomnia Without insomnia 
Percent difference in wake-up   
Model 1c   −13.43 (−38.7, 7.2) −10.65 (−37.6, 11.0) −6.58 (−16.6, 2.6) −4.52 (−14.2, 4.3) 
Model 2d −14.49 (−40.5, 6.7) −15.93 (−48.1, 9.2) −6.53 (−16.4, 2.5) −4.31 (−15.2, 5.6) 
Model 3e −10.21 (−36.0, 10.7) −14.34 (−46.9, 11.0) −5.83 (−15.6, 3.1) −3.39 (−14.6, 6.7) 
Model 4f  −8.39 (−34.1, 12.4) −10.71 (−41.5, 13.4)  −5.00 (−14.7,3.9) −1.24 (−11.8, 8.4) 
Percent difference in cortisol awakening response (CAR) 
Model 1c -28.43 (-68.4, 2.0) 0.97 (−13.9, 18.4) −10.43 (−25.2, 2.6) 1.15 (−6.2, 9.0) 
Model 2d -26.65 (-71.7, 6.6) 2.21 (−14.6, 22.4) −9.44 (−24.6, 3.9)  2.32 (−5.7, 11.1) 
Model 3e  −36.89 (−85.5, −1.0)§ 2.98 (−13.9, 23.2) −12.68 (−29.0, 1.5)   2.53 (−5.6, 11.4) 
Model 4f −31.93 (−71.5, −1.5)§  0.16 (−16.9, 20.8) −10.52 (−23.6, 1.2) 0.87 (−7.4, 9.8) 
Percent difference in early decline 
Model 1c 5.48 (−13.5, 28.7) 3.89 (−9.1, 19.3) 3.94 (−4.4, 13.0) −0.04 (−8.1, 7.4) 
Model 2d 3.70(−16.5, 28.8) 6.12 (−9.0, 23.7) 2.84 (−6.2, 12.8) −1.26 (−9.7, 6.5) 
Model 3e 5.65 (−15.7, 32.5) 5.12 (−9.7, 22.4) 2.64 (−7.2, 13.5)   −2.06 (−10.6, 5.8) 
Model 4f 2.29 (−16.6, 25.5)    3.11 (−11.8, 20.6)  0.80 (−8.0, 10.5)   −3.59 (−12.8, 4.9) 
Percent difference in late decline 
Model 1c  3.39 (1.2, 5.6)** 1.37 (−0.2, 2.9) 1.11 (0.3, 2.0)* 0.87 (0.2, 1.6)* 
Model 2d 3.53 (1.3, 5.8)* 1.37 (−0.3, 3.1) 1.17 (0.3, 2.0)* 0.94 (0.2, 1.7)* 
Model 3e 3.68 (1.4, 6.0)* 1.30 (−0.4, 3.0) 1.32 (0.4, 2.2)* 0.98 (0.3, 1.7)* 
Model 4f 3.55 (1.2, 6.0)*  1.61 (−0.1, 3.4)  1.26 (0.3, 2.2)* 1.22 (0.5, 2.0)* 
Summary measures of cortisol 
Percent difference in wake-to-bed slope 
Model 1c 2.93 (1.0, 4.9)* 1.82 (0.5, 3.1)* 1.12 (0.3, 1.9)* 0.92 (0.3, 1.5)* 
Model 2d 2.98 (1.1, 4.9)** 2.07 (0.7, 3.5)* 1.04 (0.3, 1.8)* 0.93 (0.3, 1.6)* 
Model 3e 3.05 (1.0, 5.1)* 1.96 (0.6, 3.4)* 1.07 (0.2, 1.9)* 0.91 (0.3, 1.5)* 
Model 4f 2.85 (1.0, 5.0)* 2.02 (0.6, 3.5)* 1.00 (0.1, 1.9)* 1.00 (0.3, 1.6)* 
Percent difference in area under the curve (AUC) 
Model 1c −9.87 (−31.4, 8.1) 4.54 (−10.4, 22.0) −4.11 (−13.4, 4.4) 1.97 (−4.3, 8.6) 
Model 2d −11.12 (−33.8, 7.7) 4.00 (−12.5, 23.6) −4.27 (−13.2, 3.9) 2.04 (−4.7, 9.3) 
Model 3e −11.51 (−34.8, 7.7) 4.43 (−12.2, 24.2) −5.97 (−15.0, 2.4) 2.30 (−4.6, 9.6) 
Model 4f −11.40 (−34.9, 8.0) 4.10 (−13.0, 24.5) −6.12 (−15.3, 2.4) 2.18 (−5.0, 10.0) 
§<0.05;   *≤0.01;   **≤0.001  
a  Insomnia symptoms  (WHIIRS), dichotomized as with insomnia (score ≥ 9) and without insomnia  
b Sleep duration was estimated as continuous (hours) and dichotomized (short sleep duration (<6hours) ) vs. longer (reference,  ≥ 
6hours to < 9hours) 
Models: 
c Model 1 : Model adjusted for day of salivary collection, time of wake-up, gender, age, race/ethnicity, and income-wealth index    
d Model 2 : Model 1 + body mass index, smoking, alcohol consumption, medications (oral and inhaled   steroids, hormone 
replacement therapy and antidepressants) and apnea/hypopnea index (AHI) 
e Model 3 : Model 2 + hypertension, diabetes, and depression 









Figure 3-1. Features of the diurnal cortisol profile 
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4. CHAPTER 4. SLEEP DURATION AND QUALITY AND HORMONAL AND CARDIOVASCULAR 
RESPONSES TO A STRESS CHALLENGE PROTOCOL 
Abstract 
Context:  
Short sleep duration and poor sleep quality are associated with adverse cardiovascular outcomes. 
Potential mechanisms include alterations in autonomic nervous system (ANS) activity and dysfunction of 
the hypothalamic-pituitary adrenocortical (HPA) axis.  
Objective:  
To examine the association of sleep duration and/or sleep quality and cardiovascular and hormonal 
responses to a stress challenge protocol. 
Design:  
Data from the Multi-Ethnic Study of Atherosclerosis (MESA) including actigraphy-based measures of sleep 
duration and efficiency and cardiovascular (heart rate (HR) and HR variability (HRV)) and hormonal 
(amylase and cortisol) responses to a stress challenge protocol were obtained from 527 participants ages 
54-93 years at MESA Exam 5 (2010-2012). 
Results:  
Neither sleep duration nor sleep efficiency were associated with exaggerated heart rate responses to 
challenge. Participants with low sleep efficiency had lower levels of high frequency heart rate variability 
(HF-HRV) at baseline than those with high sleep efficiency (fully adjusted model 0.58, 95% CI 1.03 to 
0.14) but there was no association between sleep efficiency and HF-HRV responses to challenge. Study 
participants who reported insomnia had greater HF-HRV orthostatic reactivity (fully adjusted model 
−0.22; 95% CI −0.444 to −0.002) than those who did not. Short sleep duration, low sleep efficiency and 
insomnia were not associated with salivary amylase or cortisol responses to challenge. 
Conclusions:  
In a population based sample, insomnia symptoms were associated with greater high frequency heart 
rate variability in response to orthostatic stress challenge.   
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Introduction   
Short sleep duration has been found in epidemiological studies to be associated with higher risk of 
coronary heart disease (CHD),8,18 subclinical cardiovascular disease (CVD),19,20 and CVD risk factors.13 
Poor sleep quality has also been found associated with CVD outcomes. Sleep difficulty was associated 
with CHD mortality in men;121 and insomnia symptoms predicted increased risk for acute myocardial 
infarct in a large cohort of men and women26 and CVD mortality in men.120 Objective poor sleep quality 
as indexed by low sleep efficiency was also associated with elevated blood pressure among adolescents.30    
Studies have also linked cardiovascular reactivity/recovery to stressors to cardiovascular-related 
outcomes. Exaggerated blood pressure reactivity to mental stress predicted hypertension in adult 
males,154 coronary artery calcium in young subjects42 and carotid atherosclerosis in middle age adults.155 
Delayed blood pressure recovery from mental stress has also been associated with carotid 
atherosclerosis.156   
Several biological pathways for the associations between sleep loss and CVD have been suggested 
including dysfunction of the hypothalamic pituitary-adrenal axis (HPA) and autonomic nervous system 
(ANS). These systems interact and reinforce each other in response to emotional stress.38,39 Stress 
system metabolites are higher during arousal and during the day and lower during sleep. For example, 
among young volunteers, evening plasma cortisol levels were higher after a whole47 and partial night48  of 
sleep deprivation than after a normal night of sleep. Plasma norepinephrine (NE) and epinephrine (E) 
were lower during sleep than during wakefulness61 and higher during nighttime hours when subjects 
were awakened than at other hours.62 Heart rate and blood pressure were lower during slow wave sleep 
(SWS) than during wakefulness.63 
Cardiovascular responses to the mental stress challenge test 
The sympathetic and parasympathetic branches of the ANS interact with each other157 such as health 
may be affected when the parasympathetic cannot modify the excessive activity of the sympathetic 
system.158 . High frequency heart rate variability (HF-HRV) is an accepted measure of parasympathetic 
tone.159 Experimental studies have also evaluated ANS markers during normal sleep and during sleep 
deprivation. For example, heart rate (HR) is slower during deep sleep than during wakefulness.160 In a 
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sample with 338 healthy adults, those who slept <6 hours/night had higher HR when awake than those 
who slept ≥6 hours.161 After 32 hours of sleep deprivation, healthy young men had higher blood pressure 
and HR and elevated normalized low-frequency HRV than without sleep deprivation.162 Insomnia was 
associated with decreased high/total frequency spectral power and increased low/high frequency spectral 
power in one study65 and SWS deprivation163 have also been associated with reduced normalized high 
frequency HRV. To our knowledge, the associations of reduced sleep duration and/or sleep quality and 
stress-induced HR/HRV responses have only been investigated in restrictive population samples. In 
studies of small samples of healthy young volunteers, the effect of sleep deprivation on subsequent 
HR/HRV responses to a mental stress has been investigated.67,68,109 However, these studies have 
inconsistent findings. 
Hormonal responses to the mental stress challenge test  
Salivary alpha-amylase (sAA), a marker of the sympathetic branch of the ANS, has also been studied in 
psychophysiological research.71,164 Amylase increases immediately after stress and returns to baseline 
levels within 10-20 minutes.75 Associations have been reported between sAA reactivity to mental and 
physical stress and plasma norepinephrine,73 shortened cardiac pre-ejection period.74 sAA reactivity was 
also correlated with heart rate (HR) and with low-frequency HRV/high frequency HRV ratio, which reflects 
sympathovagal balance.73,75 A few studies have examined the association of sleep with sAA responses to 
mental stress, but these have been restricted to children165 or healthy young adults.101 No reported study 
to our knowledge has evaluated the association of habitual sleep characteristics with sAA mental 
reactivity and/or recovery in a population-based sample.  
Diurnal cortisol patterns are markers of the HPA, and cortisol secretion can also increase in response 
to acute mental stress (probably due to pulsatility cortisol).166 Attenuated cortisol reactivity to mental 
stress has also been found in some circumstances such as in smokers167 and depression.168 Animal 
studies have found association between sleep alterations and cortisol responses to stress.169 This 
association has also been investigated in human but only in restricted population samples such as 
children170 and women.89  
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Despite evidence linking sleep to sympathetic and parasympathetic activity as well as stress 
reactivity to cardiovascular outcomes, only a few small experimental studies have examined how sleep 
affects cardiovascular reactivity to a stress challenge. Some have found associations between sleep 
deprivation and autonomic alterations67,68,109 but others did not.69 To our knowledge, only one study has 
evaluated the effect of habitual short sleep duration on subsequent HR and HRV responses to a stress 
challenge,87 but this study was restricted to a small sample of young adults. Indeed, there is lack of 
studies of sleep alterations and hormonal responses to a stress challenge. 
Aims of the study 
Establishing a link between short and/or poor sleep and altered cardiovascular and hormonal 
responses to a stress challenge is important to establishing whether sympathetic/parasympathetic 
alterations are part of the pathophysiologic mechanisms linking sleep to subsequent cardiovascular 
events.  
We hypothesized that: (1) participants whose sleep was short or of poor quality would have higher 
level heart rate (HR) and higher value of amylase and cortisol at baseline and lower level high-frequency 
heart rate variability (HF-HRV) at baseline than individuals who slept longer or better; (2) participants 
whose sleep was short or of poor quality would have greater HR, greater amylase and cortisol reactivity 
and reduced HF-HRV reactivity to mental and orthostatic stress challenges than individuals who slept 
longer or better; (3) participants whose sleep was short or of poor quality would have slower HR, HF-HRV 
and amylase and cortisol recovery from stress to baseline than individuals who slept longer or better.   
Methods 
Participants 
The Multi-Ethnic Study of Atherosclerosis (MESA) is a longitudinal study designed to investigate risk 
factors for subclinical CVD. In 2000-2002, MESA recruited 6814 men and women to MESA Exam 1. At 
recruitment, participants were 45-84 years old, free of clinical CVD, and included six US communities. 
MESA was approved by the IRB at each field center, and all participants gave written informed consent at 
each exam.  Our sample is a subset of MESA study participants, those from the Columbia, UCLA, and 
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John Hopkins field centers who completed the challenge test protocol (Stress study) and sleep 
assessments (Sleep study) during MESA Exam 5 in 2010-2012.  
The Stress study excluded participants with night shift jobs. The Sleep study excluded participants 
that used oral airways support devices, nocturnal oxygen or nightly CPAP. We also excluded participants 
with <3 hours/night (n= 11) and participants with ≥9 hours/night (n= 11) average sleep duration from 
analysis. 
A total of 1119 participants were enrolled in the cardiovascular (HR, HRV indices) part of the 
challenge test. We excluded 230 participants because of missing HR data at all 4 measurements in the 
protocol, failure to complete either mental stress tasks, or colorblindness. We excluded 362 additional 
participants who did not have actigraphy data. Our final analytic data set was based on 527 persons with 
3450 HR/HRV measures (See Figure 4-1).  
In the hormonal (amylase and cortisol) part of the challenge test, a total of 1040 participants were 
enrolled, providing 4040 salivary samples. Before we merged the stress data to the sleep data, we 
followed a few exclusion criteria on the cortisol data. We excluded participants that were missing all 4 
saliva samples for the entire challenge test, individual samples with cortisol values of 0 nmol/L or over 
100 nmol/L, participants who were blind color. The final sample before merging included 992 
participants. From this group, 420 participants did not have actigraphy data; therefore, they were 
excluded reducing our sample to 572 persons with 2242 salivary samples. We further excluded 
participants who were using steroids and/or hormone replacement therapy (n=40). The final analytic 
data for cortisol was 532 persons with 2085 salivary samples. For amylase, we excluded participants who 
were missing all 4 saliva amylase values (n=18) or whose values were in the top 1% of the baseline 
sample (n=10 observations). We then excluded participants who were color blind or failed to complete 
both mental tasks (n=35), or who did not have actigraphy data (n=424). We further excluded 
participants who used betablockers (n=104) and/or oral steroids (n=5). For amylase the final analytic 




The MESA Sleep protocol included 7-day actigraphy (Actiwatch Spectrum, Philips Respironics, Murrysville, 
PA), a sleep diary, and a sleep questionnaire. Actigraphic data during 30-second epochs were scored as 
sleep or wake by Actiware-Sleep®v.5.59 analysis software (Mini Mitter Co., Inc.). A validated algorithm134 
was used to calculate the activity count for each epoch. Intra-scorer intraclass correlation coefficients for 
average sleep duration and sleep efficiency were 0.91 and 0.97.  
Sleep variables were averaged across all nights that the actigraph was worn. Sleep duration was 
defined as the average duration of sleep between sleep onset (sleep start time) and morning wakening 
(sleep end time) while in bed after “lights off.”  It was calculated by dividing the sum of the recorded 
minutes of sleep by the total number of main sleep periods. Sleep duration <6 hours was defined as 
“short” and ≥6 hours as “longer,” consistent with previous studies. Sleep duration was also analyzed as 
at cut point of 7 hours.  Sleep efficiency was defined as the percentage of time in bed after “lights off” 
spent sleeping. It was calculated by dividing the sum of sleep minutes by the sum of minutes after “lights 
off” during main sleep intervals recorded, and multiplying by 100. Sleep efficiency was categorized as 
“low” (<85%) or “high” (≥85%) consistent with previous studies. Insomnia, a subjective measure of 
sleep quality, was assessed based on self-report using the Women’s Health Insomnia Rating Scale 
(WHIIRS), a 5-item questionnaire design to evaluate insomnia symptoms. The summary score ranged 
from 0 to 20. A score of ≥9 is considered clinically significant insomnia.135 Naps were assessed from the 
actigraphy data and defined as the average sleep time in naps per day across all days when only naps of 
≥15 minutes duration were counted. 
Stress Challenge Protocol (Mental and Orthostatic Stress) 
Participants were asked to minimize physical exercise during the hour preceding the test and not to take 
large meals, drink coffee, or smoke. After arriving at the laboratory and receiving instructions, each 
participant was connected to physiological monitors. Participants were instructed to remain silent 
throughout the protocol.   
Two psychological stress tasks were administered via computer during a standard laboratory 
psychophysiology protocol while participants were in the seated position. For both tasks, participants 
62 
 
were told their performance on the tasks would be evaluated for both speed and accuracy. The protocol 
began with a resting baseline (11 minutes) followed by two mental stress tasks (6 minutes each) and a 
corresponding recovery period after each task (6 minutes each).  
Mental stressors: Tasks were presented on a computer monitor; participants entered responses on a 
numeric keypad with their dominant hand. Tasks administration timing was controlled and synchronized 
to the physiological data acquisition via microcomputer. The order of the two tasks was varied randomly 
among participants and it was counterbalanced between subjects to minimize order effects. The Morgan 
and Turner Hewitt (MATH) task57 involved the presentation on a computer screen for 1.5 seconds of pairs 
of numbers to be added or subtracted. Then, the word “equals” for 1.0 sec; followed by a possible 
answer to the problem for 1.0 sec, during which the participant used a keypad to indicate whether the 
presented solution was correct or not. Problems were ranked along five difficulty levels; response 
accuracy on each trial adjusted the difficulty of the next trial. A modified version of the Stroop color-word 
conflict task involved the presentation of one of four-color name words (blue, green, yellow or red) on a 
screen in a font color that either did or did not match the color name. When the color name stimulus 
appeared on the screen, the participant had to press the key on a keypad corresponding to the color of 
the font. To standardize the level of engagement, the presentation rate increased with better 
performance and decreased with poorer performance.   
Following the mental tasks and their recovery periods, participants completed a 6-minute physical 
challenge test (orthostatic stress) that consisted of assuming and holding a standing position. This last 
period was followed by a 30-minute recovery period. Participants were continuously monitored by 
electrocardiogram (ECG) to collect HR and HRV data throughout the protocol (See Figure 4-2 ). 
Heart rate (HR) and HR Variability (HRV) 
Continuous measures of ECG were recorded during each period in the protocol. ECG electrodes were 
placed on the right shoulder, the left anterior axillary line at the 10th intercostal space, and the right 
lower quadrant. Analog ECG signals were digitized at 500 Hz by a Datacq9 cardiopulmonary monitor 
(Medelex, Inc., New York, NY) and passed to a microcomputer for R-wave detection implemented by 
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custom-written software (Graphical Acquisition, and Marking; Author: Delano MacFarlane, Ph.D.), 
resulting in an RR interval time series.  Errors in marking of R-waves were corrected interactively.171,172 
Heart Rate Variability (HRV). Mean HR and the standard deviation of the RR interval (SDRR), the 
root mean squared successive difference (rMSSD), and spectral power in the low (0.04-0.15 Hz (LF)) and 
high (0.15-0.40 Hz (HF)) frequency bands were computed from 5-min epochs using an interval method 
for computing Fourier transforms.173 Prior to analysis, the RR interval was filtered using a Hanning 
window,174 and power in the LF and HF bands is summed and adjusted for attenuation produced by the 
filter.174 Time and frequency-domain HRV indices were expressed in ms and ms2 respectively, and were 
log-transformed to achieve normal distribution. 
For this dissertation, we will focus only in one of the HRV indices, the high-frequency HRV (HF-HRV) 
because this index has clearly been showed to reflect the parasympathetic function of the ANS whereas 
low-frequency HRV interpretation is still not clear. Besides, the time-domain HRV indices were highly 
correlated to HF-HRV.  
Saliva collection  
Four salivary samples were collected using a cotton oral swab during the challenge protocol: after a 
resting period at baseline, which was approximately 13 minutes since participants entered the exam 
(Sample #1); immediately after the completion of the mental tasks and their respective recovery periods 
(Sample #2), around 38 min after Sample # 1; after completion of the orthostatic stress (Sample #3) – 
around 17 min after Sample # 2, and after the 30-minute recovery period at the end of the stress 
challenge protocol (Sample #4) – around 30 min after Sample 3.  
Salivary samples were stored at -200 C until analyses. After thawing, salivettes were centrifuged at 
3,000 rpm for 5 min.  Salivary cortisol level was determined using a commercially available 
chemiluminescence assay with high sensitivity (0.16 ng/mL) (IBL-Hamburg, Hamburg, Germany). Intra- 
and inter-assay coefficients of variation for the assay were <8%. Concentrations of alpha-amylase in 
saliva were measured using an enzyme kinetic method.164 Intra- and inter-variability coefficient of 




Covariates used for for analysis of HR and HRV 
Models of the association of sleep with HR/HRV were adjusted for factors known to impact heart 
rate,175 specifically  age, gender, race/ethnicity,(African American, Hispanic, or white, income-wealth 
index, body mass index (BMI, kg/m2), smoking status and alcohol consumption as of MESA Exam 5. 
Smoking status was categorized as current and recent smoker (quit less than a year ago), past smoker 
(quit more than a year ago), or never smoker. Alcohol consumption was classified as yes/no. Other 
covariates were diabetes and use of medications. Diabetes mellitus status was categorized according to 
the 2003 criteria of the American Diabetes Association as normal, impaired fasting glucose, untreated 
diabetes, and treated diabetes. We also classified diabetes status as no (normal) vs. yes (otherwise). Use 
of medications was categorized as yes if the participant used anti-hypertensive medications, medications 
for sleep and mood or sympathomimetic medications or no if the participant did not use those specific 
medications. Analyses were also adjusted for sleep efficiency when the main predictor was sleep duration 
and for sleep duration when sleep efficiency was the main predictor. Additionally, we adjusted for the 
apnea hypopnea index (AHI), including only apneas and hypopneas associated with ≥3% desaturation, 
and for naps defined as the average sleep time in naps per day across all days in the recording counting 
only naps with 15 minutes or more of sleep time. We did not adjust for hypertension but we adjusted for 
use of anti-hypertensive medication.  
Covariates used for analysis of amylase and cortisol 
For amylase, analysis involved the same covariates as above. Use of medications also included 
hormone replacement therapy and inhaled steroids. Additionally, we adjusted for sleep duration or sleep 
efficiency, and for the apnea hypopnea index (AHI).  
Statistical Analyses 
We examined participant characteristics by categories of sleep duration and efficiency. Differences in 
outcome variables and covariates by these categories were evaluated by ANOVA, Kruskall Wallis test or 
chi-square tests. HR, HRV, amylase and cortisol were transformed using the natural logarithm because of 
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skewed distribution. We used linear mixed effect models to account for the intraindividual correlation of 
the repeated measures of the outcomes.  
 Modeling HR and HRV  
Linear mixed effects models were used to estimate associations of sleep with HR and HRV responses 
to the stress challenge. In these models repeated measures of the outcomes were modeled as a function 
of stress task period, sleep, and interactions of sleep with task period in order to estimate associations of 
sleep with stress reactivity and recovery. Stress task period was modeled using three dummy variables 
representing three periods (with baseline period as reference group): mental stress task, recovery from 
mental stress, and orthostatic stress task. Up to 7 repeated measures were available for each individual 
(two at baseline, one during each of the mental stress periods, one during each of the recovery periods 
from mental stress, and one during the orthostatic challenge). Models included a random intercept for 
each person (to account for correlation between repeated measures over time within a person) and 
random slope of mental stress task indicator to allow for interindividual variability in reactivity. Robust 
standard errors were reported. Covariates were entered in the models as main effects and as two-way 
interaction terms with each of the stress task periods.  
HR/HRV responses to stress challenge analyzed in this study were: (1) mental stress reactivity 
response (HR/HRV at stress task – HR/HRV at baseline); (2) recovery from stress task response (HR/HRV 
at recovery − HR/HRV at stress task); (3) orthostatic reactivity response (HR/HRV at orthostatic – 
HR/HRV at baseline). A more positive value of the HR stress reactivity response meant greater HR 
reactivity. A more negative value of the HRV stress reactivity response meant greater HRV reactivity 
during the stress challenge task(s). A more negative value of the HR recovery response meant greater HR 
recovery. A more positive value of the HRV recovery response meant greater HRV recovery from the 
stress challenge task(s). (See Figure 4-3) 
A sequence of models was run with various adjustments. Model 1 was adjusted for continuous age, 
gender, race/ethnicity and income-wealth. Model 2 included covariates in Model 1 plus sleep efficiency 
(when sleep duration was the main outcome) or sleep duration (when sleep efficiency or insomnia was 
the main outcome) and body mass index, smoking, alcohol use, diabetes and medications 
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(antihypertensive medications, antidepressants, sympatho-mimetic medications and medications for sleep 
and mood). Model 3 was further adjusted for covariates included in Model 2 plus apnea and Model 4 was 
adjusted for covariates included in Model 3 plus naps (hr/day).   
Modeling amylase and cortisol  
To analyze the associations of sleep measures with amylase/cortisol responses to the stress 
challenge we simultaneously modeled the responses of amylase to the entire stress challenge protocol 
using piecewise mixed models with 2 knots. This modeling used all 4 salivary samples, and the knots 
were chosen based on the time when 2nd and 3rd samples were collected (on average 38 minutes and 
55 minutes after the start of the stress challenge protocol). The model estimates associations of 
predictors with change in amylase/cortisol levels over each response over the entire exam period. Models 
also included individual random intercept and random slopes on the first and third spline of time. All 
covariates were centered with respect to the grand mean when included in the models and were entered 
in the models as main effects and also as two-way interaction terms with the 3 spline pieces. Robust 
standard errors are reported. 
 Amylase/cortisol responses to stress challenge analyzed in this study were: (1) mental stress 
reactivity response (2nd sample – 1st sample); (2) orthostatic reactivity response (3rd sample – 1st 
sample); (3) recovery from stress task response (4th sample − 2nd sample). A large value of the stress 
reactivity response meant that amylase/cortisol levels rose sharply after the stress challenge task(s). A 
large value of the recovery response meant that amylase/cortisol levels fell sharply after the stress 
challenge). (See Error! Reference source not found.) 
A similar sequence of models was used as above except that for amylase we adjusted for 
hormone replacement therapy and inhaled steroids, and for cortisol we did not adjust for 
sympathomimetic medication. For both amylase and cortisol, we did not adjust for naps.  
Results 
The 527 participants included 285 women and 242 men from three different race/ethnic backgrounds, 
Hispanic (42%), African-American (31%), and white (27%). Participant characteristics classified 
according to sleep duration, sleep efficiency and insomnia are shown in Table 4-1 and Supplemental 
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Table D-1. The unadjusted mean (± S.D.) log-transformed HR (log(beast/min)), HF-HRV (log(sec2)) and 
amylase (log(nmol/L) at baseline, and responses to the stress challenge by sleep duration, sleep 
efficiency and insomnia are shown in Supplemental Table D-2, Supplemental Table D-3, Supplemental 
Table D-4, and Supplemental Figure D-1, Supplemental Figure D-2 and Supplemental Figure D-3. 
We expect that heart rate and amylase/cortisol increases with mental and orthostatic stress and 
declines during recovery whereas HF-HRV decreases with mental and orthostatic stress and increases 
during recovery. In our study, in the whole sample, we observed the expected direction during the stress 
challenge (see Error! Reference source not found.). 
Heart rate (HR) and HF-HRV responses to the stress challenge 
Table 4-2 shows the estimated log transformed heart rate in beats/min and 95% CIs in heart rate at 
baseline and in response to the stress challenge comparing  short (< 6 hours) and longer (≥ 6 hours) 
sleep duration, low and higher sleep efficiency and with and without insomnia. There was a difference in 
baseline levels of heart rate between short sleepers and longer sleepers in models 3 and 4 but no 
association of sleep duration with heart rate reactivity or recovery ( Table 4-2, first column). Neither low 
sleep efficiency nor insomnia was associated with exaggerated heart rate responses to the stress 
challenge (Table 4-2, second and third column). When we explored 7 hours as a cut point for sleep 
duration, participants who slept <7 hours/night had greater heart rate reactivity in models 2 and 3 but 
not in model 4 (Supplemental Table D-5, second column). 
Table 4-3 shows the estimates and 95% CIs in HF-HRV at baseline and responses to the stress 
challenge between short (< 6 hours) and long (≥ 6 hours) sleep duration, sleep efficiency and insomnia. 
There was no HF-HRV differences at baseline nor at responses to the stress challenge between 
participants who slept <6 hours/night that those who slept ≥6 hours/night (Table 4-3, first column). 
Participants with low sleep efficiency had lower levels of HF-HRV at baseline than those with higher sleep 
efficiency (estimate at fully adjusted model 0.58, 95% CI 1.03 to 0.14) but there was no association 
between low sleep efficiency and exaggerated HF-HRV responses to the stress challenge (Table 4-3, 
second column). Study participants who reported insomnia had greater HF-HRV orthostatic reactivity 
(fully adjusted model −0.22; 95% CI −0.44 to −0.002; P <.05) than those who did not (Table 4-3, third 
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column). When we explored a cut point of short sleep duration at 7 hours, participants who slept <7 
hours/night had significantly lower HF-HRV levels at baseline than those who slept ≥7 hours/night in all 
models and also those who slept <7 hours/night showed significantly greater HF-HRV recovery from 
mental stress than those who slept ≥7 hours/night (Supplemental Table D-6, second column).   
We evaluated the effect modification of naps for HR/HF-HRV but did not find evidence that naps 
moderated the association between sleep duration and HR/HF-HRV responses. 
Amylase and cortisol responses to the stress challenge test 
Table 4-4 shows the estimates and 95% CIs in amylase at baseline and responses to the stress 
challenge between short (< 6 hours) and long (≥ 6 hours) sleep duration, sleep efficiency and insomnia. 
There were no differences in baseline levels of salivary amylase between participants who slept < 6 hours 
than those who slept ≥6 hours/night (Table 4-4 , first column). Participants with low sleep efficiency had 
higher levels of amylase at baseline than participants with high sleep efficiency (estimate at fully adjusted 
model 0.45; 95% CI 0.04 - 0.86). However, sleep efficiency was not associated with amylase responses 
to the stress challenge test (Table 4-4 , second column). Insomnia (Table 4-4, third column) was not 
associated with amylase responses to the stress challenge test. 
Table 4-5 shows the estimates and 95% CIs in cortisol at baseline and responses to the stress 
challenge between short (< 6 hours) and long (≥ 6 hours) sleep duration, sleep efficiency and insomnia. 
Participants who reported insomnia symptoms had higher levels of cortisol at baseline than participants 
who did not (estimate at fully adjusted model 0.23; 95% CI 0.08 - 0.35). However, insomnia was not 
associated with cortisol responses to the stress challenge test (Table 4-5 , third column). 
Discussion  
We found no evidence that short sleep duration is associated with greater heart rate reactivity to 
mental stress challenge compared to longer sleep duration. We found that participants reporting 
insomnia symptoms had greater HF-HRV orthostatic reactivity than those who did not. We also found no 
evidence that short sleep duration and/or low sleep efficiency are associated with greater amylase 
reactivity to mental stress challenge compared to longer sleep duration and/or high sleep efficiency. 
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Our data provide some support for the hypothesis that difficulties of sleep may potentiate the effect 
of stress challenge on the cardiovascular indices, in that insomnia was associated with greater orthostatic 
reactivity. Although it has been reported that differences between seated position and supine position in 
the ANS are small,176 we found that insomniacs had greater HF-HRV orthostatic reactivity than non-
insomniacs. We also found differences in heart rate and HF-HRV in the groups of short vs. longer sleep 
duration and low vs. high sleep efficiency, respectively, at baseline.  
Sleep loss may potentiate the effect of the challenge test on the cardiovascular indices as has been 
shown in a few experimental studies. For example, a study with 18 healthy volunteers,67 between 19 and 
36 years old, examined the relationship between sleep deprivation and CV reactivity. The study found 
increased normalized LF-HRV and decreased normalized HF-HRV at baseline after 12 hours of sleep 
deprivation during a reaction-time testing and a seated position.  Another study, a crossover-controlled 
experiment, with 20 healthy young volunteers, examined cardiovascular reactivity to a stress challenge 
test involving a Stroop color task and a speech task. The speech task had exaggerated greater effect on 
systolic blood pressure (SBP) reactivity when subjects had had a night of total sleep deprivation than 
when they had had a night of normal sleep.68 HR did not differ in the two sleep situations for any of the 
stress tasks. In a third study, mental stress was linked to greater HR reactivity to and slower HR recovery 
from the stressors among 28 subjects after 24-hours of total sleep deprivation.109 In a more recent study, 
79 healthy young men aged 18-30 years old underwent actigraphy for sleep parameters for a week 
before a stress protocol that involved three tasks: Stroop color-word interference, a multisource 
interference task, and a speech preparation and delivery task, all of them followed by a period of 
recovery. The study found an association of habitual short sleep duration with decreased HF-HRV during 
the stress tasks. Short sleep duration was also associated with greater HR during recovery, but the 
association disappeared after adjustment for naps.87 To our knowledge, this is the only study that has 
examined these associations in habitual sleep.  
In an extended analysis, when we computed short sleep duration as <7 hours, participants had 
greater HR reactivity to mental stress than the group with longer sleep duration (≥7 hours) in a model 
that included demographic and behavioral factors, medications and sleep apnea, but this association was 
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attenuated when we further adjusted for naps. Naps seemed to compensate for short sleep. In our 
sample, those who slept fewer hours at night had longer daytime sleep. For example, 173 participants 
who slept <6h napped for a mean of 60 (± 54) min, and 358 participants who slept <7 hours napped for 
a mean of 48 (± 42) min whereas longer sleepers, either ≥6 hours or ≥7 hours, napped for a mean of 30 
(± 30) minutes. The effect that naps have on people seems to depend on the group of age. For example, 
in a recent study in healthy young volunteers, 30-minute naps after sleep restriction in a laboratory 
setting restored urinary norepinephrine levels that had been increased after two hours of sleep restriction 
the night before.177 In another study among 104 volunteers with a mean age of 20 years, 45- to 60-
minute naps facilitated blood pressure recovery from mental stressors.178 However, in a large cohort of 
older women, daily napping for total sleep duration of 8 or 9 hours was associated with increased 
mortality from all causes excluding cancer.179 In another cohort of octogenarians, disturbed sleep was 
associated with higher odds of naps independent of total sleep time.180  
The influence of sleep characteristics on subsequent hormonal responses to stressors has been 
examined in animals169 and in restricted population samples. For example, in a study of 31 children170   
aged 10-17 years old, sleep problems within two weeks prior to the stress challenge were evaluated to 
stress challenge responses. The protocol involved three stressors: speech, mental arithmetic, and mirror 
tracing tasks. Subjective poor sleep quality (assessed as sleep-wake behavior problems) was associated 
with attenuated cortisol responses to stress but short sleep duration was not associated with cortisol 
stress reactivity. In another study, 64 women, aged 37±10 years,89 were exposed to a battery of six 
Stroop color-word interference trials, and 7 day-actigraphy previous to the stress challenge. Poor sleep 
quality (assessed as low sleep efficiency) measured on the previous night predicted attenuated cortisol 
reactivity, but short sleep duration did not. 
Contrary to previous studies, our study examined how chronic habitual short sleep duration and/or 
poor sleep quality affects subsequent cortisol responses to acute mental stress in an elderly population. 
We did not observe an association between sleep quantity or quality and cortisol reactivity.  We found no 
associations between short sleep duration and greater amylase reactivity to mental stress, either. 
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Our study has some limitations. First, we may have missed the effect of short sleep duration or low 
sleep efficiency on the hormonal responses to a stress challenge protocol because of lack of power.  
Second, 88% of our study participants were taking at least one prescribed medication suggesting a high 
prevalence of medical conditions. Although we either excluded or adjusted for almost all medications that 
are thought to interact with the secretion of cortisol and/or amylase, we may have either over- or 
underadjusted our models. In the amylase analyses, for example, we had to exclude 106 participants 
who used beta blockers. Third, many, perhaps most, of our participants had several chronic conditions 
that could have attenuated the cortisol responses to acute stress in the laboratory. Fourth, because ours 
is a cross-sectional study, we cannot draw conclusions about cause and effect. Fifth, the short and longer 
sleepers and the poor and good sleepers did not differ with respect to stress scores evaluated at baseline 
and after each mental stressor indicating that the subjective impression of stress was similar in both 
groups. 
However, our study also has strengths. First, the MESA Study is an epidemiological study of a 
population-based sample with heterogeneous background, from which we collected 4 measures of 
salivary cortisol and amylase and physiological CV markers (HR and HRV) in response to a standardized 
stress challenge protocol. To our knowledge, ours is the first study of the amylase response to stress and 
alterations of sleep in a large community-based sample. Second, we have objective measures of sleep, 
collected under “normal” habitual circumstances at home without imposing sleep restrictions. We assume 
that we captured actual sleep habits in our population. Third, we count with extended data of potential 
confounders in the relationship sleep and markers of stress such as apnea. 
In summary, we have not found significant evidence suggesting the association of short sleep 
duration with greater heart rate reactivity to mental stress challenge compared to longer sleep duration.  
However, some of our data suggest that insomnia is associated with orthostatic reactivity. We also found 
differences at baseline on the groups of short and longer sleepers with respect to HR, and on the groups 
of poor and good sleepers with respect to HF-HRV, amylase and cortisol. This finding is important. We all 
have to deal with mental stressors in our everyday life, and it is useful to know that reduced sleep 
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Table 4-2. Mean differences in log-transformed heart rate (log (beats/min)) at baseline and mean 
differences in responses to challenge by sleep duration, sleep efficiency and insomnia symptoms (N = 
3450 observations, 527 persons) 
 Sleep Duration* Sleep Efficiency Insomnia 
 ( < 6 hrs vs. ≥ 6 hrs) (low vs. high) (Yes vs. No) 
 Estimate and 95% C.I. Estimate and 95% C.I. Estimate and 95% C.I. 
Baseline 
Model 1 0.0255 -0.0056 0.0566 0.0255 -0.0248 0.0759 0.0122 -0.0174 0.0417 
Model 2 0.0289 -0.0021 0.0598 0.0139 -0.0361 0.0639 0.0106 -0.0187 0.0400 
Model 3 0.0360 0.0033 0.0686 0.0112 -0.0411 0.0635 0.0046 -0.0265 0.0357 
Model 4 0.0404 0.0070 0.0739 0.0096 -0.0427 0.0620 0.0060 -0.0247 0.0367 
Reactivity to Mental Stress1 
Model 1 0.0075 -0.0030 0.0180 -0.0029 -0.0175 0.0116 0.0000 -0.0096 0.0097 
Model 2 0.0079 -0.0022 0.0181 -0.0046 -0.0189 0.0096 -0.0004 -0.0098 0.0090 
Model 3 0.0055 -0.0052 0.0161 -0.0080 -0.0219 0.0060 0.0018 -0.0080 0.0117 
Model 4 0.0043 -0.0074 0.0160 -0.0077 -0.0216 0.0062 0.0016 -0.0082 0.0115 
Recovery from Mental Stress2 
Model 1 0.0005 -0.0080 0.0089 0.0038 -0.0071 0.0147 0.0049 -0.0031 0.0129 
Model 2 -0.0003 -0.0086 0.0080 0.0033 -0.0074 0.0141 0.0055 -0.0024 0.0133 
Model 3 0.0013 -0.0074 0.0100 0.0047 -0.0060 0.0155 0.0039 -0.0043 0.0122 
Model 4 0.0033 -0.0062 0.0128 0.0042 -0.0066 0.0151 0.0044 -0.0039 0.0126 
Reactivity to Orthostatic Stress3 
Model 1 0.0077 -0.0048 0.0202 -0.0061 -0.0214 0.0092 0.0084 -0.0040 0.0208 
Model 2 0.0072 -0.0052 0.0195 -0.0090 -0.0251 0.0071 0.0083 -0.0042 0.0207 
Model 3 0.0094 -0.0040 0.0227 -0.0111 -0.0284 0.0061 0.0083 -0.0051 0.0216 
Model 4 0.0099 -0.0050 0.0248 -0.0111 -0.0284 0.0062 0.0082 -0.0051 0.0216 
*Short sleep duration was categorized as <6 hours vs. longer ≥6 hours (reference)   
1
 Reactivity to Mental Stress by Sleep Duration = HR at mental stress - HR at baseline 
2
 Recovery from Mental Stress by Sleep Duration = HR at recovery  - HR at mental stress 
3
 Reactivity to Orthostatic Stress by Sleep Duration = HR at orthostatic stress  - HR at baseline 
 
Note: A more positive coefficient for the reactivity associated with shorter sleep means a greater increase in HR 
response to the stressor (greater reactivity); a more negative coefficient for recovery associated with shorter sleep 
means a greater HR recovery from the stressor (Error! Reference source not found., Supplemental Table D-2 
nd Supplemental Figure D-1)   
 
Model 1 = age, gender, race/ethnicity, income-wealth index.  
Model 2 = model 1 plus body mass index, smoking, alcohol consumption, medications (antihypertensive, antidepressants, 
sympatho-mimetic medications and medication for sleep and mood), diabetes and sleep efficiency.  
Model 3 = model 2 plus apnea.  




Table 4-3. Mean differences in log-transformed HF-HRV (log (msec2)) at baseline and mean differences in 
responses to challenge by sleep duration, sleep efficiency and insomnia symptoms (N = 3450 
observations, 527 persons) 
 Sleep Duration* Sleep Efficiency Insomnia 
 ( < 6 hrs vs. ≥ 6 hrs) (low vs. high) (Yes vs. No) 
 Estimate and 95% C.I. Estimate and 95% C.I. Estimate and 95% C.I. 
Baseline 
Model 1 0.05 0.23, 0.32 0.52 1.01, 0.04 0.03 0.29, 0.23 
Model 2 0.06 0.20, 0.33 0.48 0.96, 0.00 0.03 0.29, 0.22 
Model 3 0.00 0.28, 0.28 0.60 1.04, 0.15 0.01 0.27, 0.25 
Model 4 0.01 0.31, 0.28 0.58 1.03, 0.14 0.02 0.27, 0.23 
Reactivity to Mental Stress1 
Model 1 0.08 0.23, 0.07 0.05 0.27, 0.17 0.14 0.29, 0.01 
Model 2 0.09 0.24, 0.06 0.01 0.24, 0.21 0.12 0.27, 0.03 
Model 3 0.05 0.21, 0.11 0.12 0.09, 0.33 0.13 0.30, 0.03 
Model 4 0.09 0.26, 0.09 0.13 0.08, 0.34 0.15 0.31, 0.02 
Recovery from Mental Stress2 
Model 1 0.04 0.09, 0.17 0.05 0.11, 0.21 0.10 0.02, 0.23 
Model 2 0.05 0.07, 0.18 0.01 0.16, 0.18 0.08 0.04, 0.20 
Model 3 0.02 0.12, 0.15 0.03 0.21, 0.15 0.08 0.05, 0.21 
Model 4 0.02 0.13, 0.17 0.03 0.21, 0.14 0.09 0.04, 0.22 
Reactivity to Orthostatic Stress3 
Model 1 0.05 0.24, 0.14 0.03 0.24, 0.17 0.20 0.41, 0.001 
Model 2 0.04 0.23, 0.14 0.00 0.22, 0.22 0.20 0.40, 0.011 
Model 3 0.10 0.30, 0.10 0.08 0.15, 0.31 0.21 0.44, 0.010 
Model 4 0.16 0.37, 0.06 0.10 0.14, 0.33 0.22 0.44, 0.002 
*Short sleep duration was categorized as <6 hours vs. longer ≥6 hours (reference)   
1
 Reactivity to Mental Stress by Sleep Duration = HF-HRV at mental stress - HF-HRV at baseline 
2
 Recovery from Mental Stress by Sleep Duration = HF-HRV at recovery  - HF-HRV at mental stress 
3
 Reactivity to Orthostatic Stress by Sleep Duration = HF-HRV at orthostatic stress  - HF-HRV at baseline 
 
Note: A more negative coefficient for the reactivity associated with shorter sleep means a greater reduction in HF-
HRV response to the stressor, a more positive coefficient for recovery associated with shorter sleep means a greater 
increase in HF-HRV during recovery. (Error! Reference source not found., Supplemental Table D-3 and 
 REF _Ref430434433 \h  \* MERGEFORMAT Supplemental Figure D-2) 
 
Model 1 = age, gender, race/ethnicity, income-wealth index.  
Model 2 = model 1 plus body mass index, smoking, alcohol consumption, medications (antihypertensive, antidepressants, 
sympatho-mimetic medications and medication for sleep and mood), diabetes and sleep efficiency.  
Model 3 = model 2 plus apnea.  




Table 4-4. Mean differences in log transformed amylase ((log (U/mL)) at baseline and mean differences 
in responses to challenge by sleep duration, sleep efficiency and insomnia symptoms (N=1736 
observations, 454 persons) 
 Sleep Duration Sleep Efficiency Insomnia Symptoms 
 ( < 6 hrs vs. ≥ 6 hrs) low vs. high Insomnia vs. non-insomnia 
 
Estimate and 95% C.I. Estimate and 95% C.I. Estimate and 95% C.I. 
Baseline 
Model  1 0.04 -0.23, 0.31 0.32 -0.04, 0.69 -0.08 -0.34, 0.18 
Model  2 0.04 -0.25, 0.33 0.41 0.01, 0.82 -0.09 -0.36, 0.18 
Model  3 0.02 -0.27, 0.31 0.43 0.02, 0.83 -0.08 -0.36, 0.19 
Model  4 -0.01 -0.30, 0.29 0.45 0.04, 0.86 -0.08 -0.35, 0.20 
Mental stress reactivity1 
Model  1 0.14 -0.04, 0.31 -0.08 -0.31, 0.15 0.03 -0.15, 0.21 
Model  2 0.18 0.00, 0.37 -0.20 -0.46, 0.06 0.05 -0.13, 0.23 
Model  3 0.16 -0.02, 0.35 -0.22 -0.47, 0.04 0.04 -0.14, 0.21 
Model  4 0.14 -0.04, 0.33 -0.21 -0.47, 0.04 0.03 -0.15, 0.21 
Orthostatic stress reactivity2 
Model  1 0.04 -0.17, 0.24 -0.28 -0.63, 0.07 0.11 -0.10, 0.33 
Model  2 0.10 -0.12, 0.32 -0.29 -0.68, 0.10 0.13 -0.08, 0.34 
Model  3 0.10 -0.12, 0.32 -0.31 -0.70, 0.08 0.10 -0.12, 0.32 
Model  4 0.06 -0.17, 0.28 -0.32 -0.73, 0.08 0.08 -0.14, 0.30 
Total recovery3    
Model  1 -0.16 -0.37, 0.04 -0.07 -0.39, 0.26 0.03 -0.16, 0.23 
Model  2 -0.10 -0.31, 0.10 0.06 -0.21, 0.34 0.02 -0.18, 0.23 
Model  3 -0.08 -0.29, 0.13 0.05 -0.22, 0.33 0.01 -0.20, 0.22 
Model  4 -0.10 -0.31, 0.10 0.05 -0.22, 0.32 -0.01 -0.22, 0.20 
 
1 the difference between amylase values at 2nd sample (mental stress) and amylase value at 1st sample (baseline)   
2 the difference between amylase values at 3rd sample (orthostatic stress) and amylase value at 1st sample (baseline)   
3 the difference between amylase values at 4th sample (at the end of the stress challenge) and amylase value at 2nd sample (mental 
stress)  
 
Note: A large value of the stress reactivity response meant that amylase levels rose sharply after the stress 
challenge task(s). A large value of the recovery response meant that amylase levels fell sharply after the stress 
challenge (Error! Reference source not found., Supplemental Table D-4  and Supplemental Figure D-3) 
 
Model 1= age, gender race/ethnicity, income wealth index. 
Model 2 = model 1 plus apnea and sleep efficiency (for sleep duration as exposure) and sleep duration (for sleep 
efficiency as exposure).  
Model 3 = model 2 plus alcohol consumption, smoking, body mass index.  
Model 4 = model 3 plus medications (antihypertensive, antidepressants, hormone replacement therapy, sympatho-




Table 4-5. Mean differences in log transformed cortisol ((log (nmol/L)) at baseline and mean differences 
in responses to challenge by sleep duration, sleep efficiency and insomnia symptoms (N=2085 
observations, 532 persons) 
 Sleep Duration Sleep Efficiency Insomnia Symptoms 
 ( < 6 hrs vs. ≥ 6 hrs) low vs. high Insomnia vs. non-insomnia 
 
Estimate and 95% C.I. Estimate and 95% C.I. Estimate and 95% C.I. 
Baseline 
Model  1 0.02 -0.15 0.18 -0.13 -0.36 0.11 0.21 0.08 0.35 
Model  2 0.02 -0.17 0.21 -0.14 -0.41 0.12 0.22 0.07 0.37 
Model  3 0.03 -0.17 0.22 -0.14 -0.41 0.12 0.23 0.08 0.38 
Model  4 0.04 -0.16 0.23 -0.16 -0.43 0.11 0.23 0.08 0.38 
Mental stress reactivity1 
Model  1 0.00 -0.10 0.10 -0.07 -0.23 0.09 -0.05 -0.14 0.05 
Model  2 -0.01 -0.12 0.11 -0.08 -0.25 0.09 -0.03 -0.14 0.07 
Model  3 -0.01 -0.12 0.10 -0.08 -0.24 0.09 -0.04 -0.14 0.06 
Model  4 -0.02 -0.13 0.10 -0.07 -0.24 0.10 -0.04 -0.14 0.06 
Orthostatic stress reactivity2 
Model  1 0.04 -0.10 0.18 -0.02 -0.17 0.13 -0.06 -0.21 0.08 
Model  2 0.04 -0.12 0.20 -0.04 -0.19 0.12 -0.09 -0.24 0.07 
Model  3 0.04 -0.13 0.20 -0.04 -0.20 0.11 -0.10 -0.25 0.06 
Model  4 0.02 -0.14 0.19 -0.03 -0.18 0.13 -0.10 -0.26 0.06 
Total recovery3    
Model  1 0.02 -0.09 0.12 0.11 -0.03 0.25 0.08 -0.03 0.18 
Model  2 0.03 -0.09 0.14 0.12 -0.03 0.26 0.06 -0.05 0.17 
Model  3 0.02 -0.09 0.13 0.11 -0.03 0.26 0.05 -0.06 0.16 
Model  4 0.02 -0.09 0.13 0.12 -0.02 0.26 0.06 -0.06 0.17 
 
1 the difference between cortisol values at 2nd sample (mental stress) and cortisol value at 1st sample (baseline)   
2 the difference between cortisol values at 3rd sample (orthostatic stress) and cortisol value at 1st sample (baseline)   
3 the difference between cortisol values at 4th sample (at the end of the stress challenge) and cortisol value at 2nd sample (mental 
stress)  
 
Model 1= age, gender race/ethnicity, income wealth index. 
Model 2 = model 1 plus apnea and sleep efficiency (for sleep duration as exposure) and sleep duration (for sleep efficiency as 
exposure).  
Model 3 = model 2 plus alcohol consumption, smoking, body mass index.  







Figure 4-1 Flow Chart of Exclusion Criteria for Participants with Cardiovascular Measures  
 
  
Participants = 1119 
Participants = 919 
 
Participants = 911 
 
Participants = 889 
 
Participants = 527 
Observations = 3450 
 
Participants missing HR/HRV 
measures at all periods (N = 200) 
Participants who did not complete 
both mental tasks (N=8) 
Color blind participants (N = 22) 
Participants with no actigraphy 
measures and extreme values of 
sleep duration (N = 362) 


























































































































































































































































































































































































Baseline Mental Stress Recovery Orthostatic







Baseline Mental Stress Recovery Orthostatic









Sample 1 Sample 2 Sample 3 Sample 4
Mean log-transformed Amylase (log (U/mL))   
For Amylase: average measure at:  
Sample 1 = at baseline 
Sample 2 = at the end of the two stress tasks and 
respective recovery periods 
Sample 3 = at the end of orthostatic stressor 
Sample 4 = at 30 minutes of recovery time after end 
of orthostatic stressor    
For HR/HRV:  
Mental Stress =  
𝑀𝑒𝑛𝑡𝑎𝑙 𝑆𝑡𝑟𝑒𝑠𝑠1 +𝑀𝑒𝑛𝑡𝑎𝑙 𝑆𝑡𝑟𝑒𝑠𝑠2
2
  
Recovery =  
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 𝑃𝑒𝑟𝑖𝑜𝑑1 +𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 𝑃𝑒𝑟𝑖𝑜𝑑2
2
   




5. CHAPTER 5. CONCLUSIONS 
SLEEP DURATION AND SLEEP EFFICIENCY, THE HYPOTHALAMIC-PITUITARY 
ADRENOCORTICAL AXIS (HPA) AND THE AUTONOMIC NERVOUS SYSTEM (ANS).  
Aims 
The overall goal of this dissertation was to study some of the mechanisms that have been proposed 
to be in the pathway from habitual short sleep duration and sleep disturbances to cardiovascular disease 
(CVD). We theorized that dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis and overactivation 
of the sympathetic nervous system (SNS) might be found in this pathway. Short sleep duration and/or 
poor sleep quality may affect health through specific physiological mechanisms, such as dysfunction of 
the HPA and/or SNS. When these systems fail to regulate themselves or each other, the body is exposed 
to adverse events. 
The three aims of this dissertation were: 1) to examine the associations of sleep duration and sleep 
quality with diurnal patterns in salivary cortisol; 2) to examine the association of sleep duration and sleep 
quality with hormonal measures and cardiovascular markers, in response to a standardized stress 
challenge protocol; and 3) to test for interaction in the association between short sleep duration and/or 
poor sleep quality and cortisol with gender, race/ethnicity, and SES.  
We hypothesized that adults with short sleep duration and/or poor sleep quality would have altered 
diurnal cortisol rhythms, in particular flatter cortisol slopes across the day than other adults. We 
hypothesized that among adults with short sleep duration and/or poor sleep quality, acute and 
momentary stress would be associated with exaggerated responses of levels of momentary cortisol, 
amylase and cardiovascular markers during a stress challenge protocol. 
Summary of results  
In Chapter 2 of this dissertation, a systematic review of the literature identified 19 studies that linked 
habitual sleep duration/sleep quality with diurnal cortisol measurements in population-based samples of 
adults. We found only two studies that linked these sleep alterations with responses to a stress challenge 
protocol in population-based sample of adults. Epidemiological studies have analyzed biological markers 
of the HPA and SNS in recent years, but few studies have addressed the mechanisms by which 
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insufficient and poor sleep may be linked to CVD. The 19 papers identified had inconsistent results, 
perhaps because of non-standardized protocols for sample collection and/or differences in analytical 
methods. Sample sizes were generally small; only a few studies had sample sizes over 500 participants. 
Therefore, interpretation of the literature is still problematic.  
Chapter 3 of this dissertation assessed the association of diurnal cortisol patterns with habitual short 
sleep duration and/or poor sleep quality, using either sleep efficiency or symptom of insomnia. We used 
piecewise mixed linear models, which have been used more recently in the analysis of diurnal cortisol in 
population-based samples because this analytical method has several advantages over approaches that 
just summarize repeated observations of the features of the diurnal cortisol such as cortisol awakening 
response (CAR), diurnal slope, and area under the curve. Mixed models are more efficient than those 
other approaches because they use all samples, can deal with different numbers of observations per 
participant, capture the non-linear pattern of the cortisol, and obtain all the diurnal cortisol features from 
a single model.  
We found that sleep duration and efficiency were associated with features of the diurnal cortisol 
profile in a population-based sample of adults. Persons who slept fewer hours or with lower sleep 
efficiency had a less pronounced decline in cortisol over the day than persons who slept more hours or 
had higher sleep efficiency. In addition, study participants with insomnia had a flatter cortisol awakening 
response (CAR) than those without insomnia, and, in stratified analyses, associations of short sleep 
duration with a less pronounced decline were stronger in persons who also reported insomnia than in 
those who did not. The associations of shorter sleep duration with a less pronounced late decline in 
cortisol over the course of the day were robust to various sensitivity analyses. Other studies have also 
found alterations in the CAR;80 our analysis did not show differences, but a trend toward decreased CAR. 
In general, we observed a flatter pattern in those with short sleep duration than in other subjects, and 
this pattern was driven by the increase of evening cortisol. This finding was consistent with our 
hypothesis in which we expected to find alterations of the HPA as a result of sleep loss. 
Chapter 4 evaluated the association between habitual short sleep duration and/or poor sleep quality 
and responses to a standardized stress challenge protocol. We used two types of measures as the 
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outcomes: hormonal (cortisol and amylase) responses and cardiovascular (heart rate (HR) and HR 
variability) responses. Cortisol and salivary amylase responses to a stress challenge did not differ by sleep 
duration group or by sleep efficiency group. The results from this analysis did not support an association 
between habitual short sleep duration and/or poor sleep quality and responses to a stress challenge 
protocol. We failed to find evidence that deficient sleep caused an overactivation of the sympathetic 
nervous system or a withdrawal of the parasympathetic nervous system in response to the stress 
challenge used in this protocol. 
Overall, the results of this dissertation show the need for increasing research on the study of 
mechanisms by which unsatisfactory sleep causes CVD. Cardiac disease is the leading cause of mortality 
among men and women in the United States. A large global case-control study, the Interheart,76 found 
that more than 90% of the population attributable risk of myocardial infarct is accounted for by nine 
modifiable risk factors. The risk factors studied were the classic risk factors found by the Framingham 
study plus several psychosocial factors. However, sleep was not investigated in this large study. 
Short sleep duration associated with evening cortisol 
In experimental studies, HPA and sleep seem to interact in several ways. The HPA axis affects sleep, but 
sleep also affects the HPA axis. Sleep onset inhibits cortisol secretion while awakening and sleep offset 
produce cortisol stimulation.181 Cortisol has been proposed to be related to health, and it has become 
important in population surveys.  Dysregulation in the regular cortisol diurnal pattern has been associated 
with diverse pathologies, such as major depression and cancer, and also with CVD mortality in at least 
one study.41  
Although the findings are mixed, a consistent pattern that seems to be emerging is the association 
of adverse outcomes with a flatter decline in cortisol over the day.182 However, findings for the CAR have 
been more mixed. For example, a larger CAR and flattened diurnal decline were found to be associated 
with work-related stress;146 flatter CAR was associated with burnout;147 a flatter slope, due to lower 
morning cortisol, was associated with home-related stress,145 lower levels at wake-up and less 
pronounced early decline in cortisol with low-socioeconomic status,136 and higher evening cortisol with 
insomnia.130 A flattened diurnal pattern was also associated with atherosclerosis in the CARDIA study.144   
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Lower CAR was associated with diabetes,126 and lower levels of awakening cortisol and a less pronounced 
decline in cortisol were associated with markers of obesity127 in the MESA Study.  
Some investigators34 have pointed out that sleep loss is a type of stress that can affect health. The 
HPA axis plays a role in the homeostatic process of the body.34 Alterations of the activity of both the 
stress systems, HPA and SNS, have been studied as two of the mechanisms through which sleep loss 
affects health outcomes in the laboratory and recently in the general population. Biological markers of 
these systems have been added to epidemiological studies. Cortisol, initially studied in urine and blood 
and more recently in saliva, is a biological marker of the HPA and is related to behavioral influences and 
health outcomes.  
Responses to stress challenge (acute stress) 
In laboratory settings, exposure to stress has been found to lead to cardiovascular and physiological 
reactivity in population-based epidemiologic studies, but very few studies have examined whether 
reactivity to stress is different among those who have shorter and/or poorer sleep than in those who 
have longer sleep duration and/or good sleep quality.   
Norepinephrine and epinephrine measures in urine had been the classic markers of the status of the 
sympathetic nervous system, but they have the disadvantage that they can be measured only in urine or 
blood; therefore measuring them in large epidemiological studies is a challenge. Most recently, salivary 
amylase had been thought to be more feasible to use in such studies, but it is note closely correlated 
with norepinephrine.    
We found that sleep duration was associated with evening cortisol; however, sleep duration was not 
associated with cortisol responses to acute stress. It is possible that the mental tasks were not 
challenging enough to induce secretion of stress hormones in this population or that participant 
emotionally withdrew from the challenge at some point during the protocol. It is possible that the 
response to the challenge depends on “competing stressors,” so that the stress in the protocol is not as 
great at the stress that the study participants face in their daily lives. Or perhaps we did not detect 
changes in the hormones because our sample lacked statistical power. We had to exclude a number of 




Although biological markers are more quantifiable than subjective variables, we still know little about the 
meaning of many biological markers at the population level. A limitation of collecting biological markers 
(cortisol) from participants at their homes is that it requires a lot of commitment on the part of the 
participant. Participants need to understand the importance of adhering to the prescribed schedule. For 
example, if the first cortisol sample of the day is not collected within a few minutes after awakening, we 
cannot tell whether we missed the CAR or the CAR did not occur. As a result, we may have 
underestimated the association between sleep duration and the CAR and been unable to demonstrate the 
importance of studying the relationship between sleep and features of the diurnal cortisol pattern.  
A second limitation of this analysis is that the cortisol and stress challenge responses were not 
assessed simultaneously with the sleep parameters. Among some of the study participants, up to two 
years elapsed between the biological sample collection and the sleep measurements. However, studies 
have shown that both sleep and cortisol parameters are relatively stable, as are the cardiovascular 
responses to the stress challenge.   
A third limitation of this analysis is that we may have failed to adjust for all confounders.  However, 
we adjusted for the variables most commonly mentioned and analyzed in the literature relevant to sleep 
and cortisol.  
Finally, we did not find an alteration of the sympathovagal balance related to sleep. Laboratory 
studies have found that sleep restriction and sleep deprivation result in alterations of the HPA and SNS.183 
However, few studies have addressed the association of these systems with sleep in a population-based 
sample. We found some evidence suggesting that the HPA is relevant to sleep alterations and CVD, but 
we did not find comparable evidence of a role for the SNS. Our power to find an effect might have been 
greater if we had used a composite of several hormones, including inflammatory markers and metabolic 
markers.  All of those markers have been proposed to be in the pathway, and they all work together. 




The findings of this dissertation have some important implications. First, people with bad sleep habits 
need to be aware that adequate sleep in both duration and quality is important to restore the body and 
to decrease the burden of stress imposed on us over the course of the day. 
Evaluating the specific mechanisms by which sleep leads to CVD is essential. If sleep were 
recognized as a CVD risk factor, the mortality rates for CVD might decline further. Lack of sleep is a type 
of stressor,34 and if persistent and chronic it may deregulate normal homeostasis and raise the allostatic 
load.184 
We also investigated potential effect modification by gender, age (54 to <68, 68 to < 75 and 75 
years old or more) and race/ethnicity (whites, African Americans and Hispanics) in the relationship of 
sleep duration and/or sleep efficiency and cortisol. We did not find effect modification by these variables. 
In analyses stratified on race/ethnicity, among whites short sleep duration was significantly associated 
with lower wake up levels in models 2 through 4, and among blacks, short sleep duration was 
significantly associated with less pronounced late decline cortisol in all models. In addition, in the group 
of participants <75 years, short sleep duration was significantly associated with less pronounced late 
decline in cortisol in all models. 
 
Conclusions 
In several laboratory studies, even one night of sleep deprivation in young healthy volunteers has been 
reported to affect the HPA and to affect the sympathetic/parasympathetic balance. Long-term of lack of 
sleep in population samples remains to be studied. In animals, lack of sleep and repeated stress causes 
alteration in some brain regions that involve cognition and feelings. It is reasonable to infer that in 
humans lack of sleep may produce similar damage. In humans, chronic circadian disruption and reduced 
sleep time are associated with elevated cortisol, increased obesity, increased oxidative stress and 
alteration in some brain regions among other consequences.35 Many hormones, including cortisol, and 
some behaviors, including sleep, have a circadian pattern.  
87 
 
Experimental studies in both animals and humans have showed that disruption of the circadian 
cycle185 produces disruption in some vital functions that, if sustained, may lead to adverse health effects. 
A common example of circadian disruption is shift work,186 which has been linked to cardiovascular 
disease, hypertension, and diabetes. Separately, preferences for a nocturnal chronotype187 or pattern of 
sleep-wake activities have also been linked to adverse outcomes such as obesity. For some individuals, a 
chosen a very early or late sleep may conflict with their regular daily schedule, contributing to insomnia 
and daytime sleepiness. Studies have reported that later chronotype is associated with unhealthy lifestyle 
and poorer health behaviors, such as overeating, smoking, alcohol, and lack of physical activity.  
Although numerous studies have found a link between sleep loss and CVD, much more research in 
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APPENDIX C Chapter 3 
 
Supplemental Table C-1 First sample time (in minutes) since self-reported wake up after deleting 
exclusions, MESA Study 
day Max P95 P90 Q3 Median Q1 P10 P5 Min 
1 185 45 30 10 4 1 0 0 0 





Supplemental Table C-2 Number of samples per subjects (after exclusions), MESA Study 
No of Samples per Subject Count of Subjects % 
2 1 0.1 
4 1 0.1 
6 1 0.2 
7 1 0.2 
8 2 0.3 
9 1 0.2 
10 4 0.7 
11 8 1.3 
12 19 3.2 
13 33 5.5 
14 91 15.2 
15 126 21.0 
16 312 52.0 






Supplemental Table C-3 Number of samples per participant day (after exclusions) 
 DAY 
No. of Samples 
per Day Participant Days* % 
Day 1 1 2 0.3 
 
2 2 0.3 
 
4 3 0.5 
 
5 13 2.2 
 
6 29 4.8 
 
7 151 25.2 
 
8 399 66.7 
Total  participant days in Day 1 599 100.0% 
Day 2 3 2 0.3  
 
4 4 0.7 
 
5 15 2.5 
 
6 43 7.2 
 
7 156 26.0 
 
8 379 63.3 
Total  participant days in Day 2 599 100.0% 
No. of Total Days 1198   
*For instance, on day 1, only 2 participants provided one sample for the whole day whereas 399 





Supplemental Table C-4  Distribution of salivary sample collection time (hours) since awakening in MESA 
 




Quartile 90th Pctl 95th Pctl 
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 0.56 0.53 0.55 0.51 0.52 0.56 0.51 
3 2.70 2.71 2.82 2.67 2.68 2.84 3.07 
4 5.01 4.59 3.95 3.40 3.50 3.82 4.15 
5 6.82 6.46 5.91 5.40 5.25 5.35 5.74 
6 11.00 10.59 9.90 9.27 8.92 8.69 8.68 
7 12.70 12.42 11.90 11.31 11.00 10.90 11.15 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplemental Table C-6 Characteristics of participants (n = 600) by mean sleep duration in hours (mean 
(SD)), MESA Study (2010-2012) 
Characteristics Number of Sleep Duration (hours)  
 participants Mean SD p-value* 
Overall 600 6.44 1.2  
Age category, years    0.2 
    54 – 64 207 6.42 1.1  
    65 – 74 211 6.42 1.2  
    75 – 84 152 6.38 1.2  
     ≥ 85   30 6.96  1.2  
Sex (% distribution)    0.001 
    Female 316 6.58  1.2  
    Male 284 6.27  1.2  
Race/ethnicity (% distribution)    < 0.0001 
    White 166 6.81  1.1  
    Black 191 6.01  1.2  
    Hispanic 243 6.51 1.2  
Study site (% distribution)    0.1 
    Columbia  265 6.32  1.2  
    Johns Hopkins 162 6.51 1.1  
    UCLA 173 6.54  1.2  
Education (% distribution)    0.8 
    Less than High School to GED 238 6.44  1.2  
    Some College to Associate Degree 181 6.39  1.2  
    Bachelor or greater 179 6.48  1.2  
Mean income (in thousands USD)    <0.01 
    Lowest  tertile 184 6.47  1.2  
    Second tertile 180 6.21  1.2  
    Highest tertile 232 6.59  1.1  
Income-Wealth Index (% distribution)    0.05 
    0 − 1   74 6.17  1.2  
    2 − 3 124 6.48  1.2  
    4 − 6 222 6.33  1.2  
    7 − 8 116 6.59 1.1  
Marital status      0.4 
    Married/Living with partner 328 6.49 1.1  
    Living without partner 259 6.41 1.2  
Body Mass Index ( % distribution)    <0.0001 
    Normal 118 6.69 1.1  
    Obesity Grade 1 238 6.54  1.2  
    Obesity Grade 2 221 6.26  1.2  
    Obesity Grade 3   23 5.68 1.1  
Smoking status (% distribution)    0.3 
    Never  327 6.44  1.2  
    Former and quit > 1 year ago 222 6.48  1.2  
    Current and former quit ≤ 1 year ago   48 6.18  1.2  
Alcohol Use Presently      0.6 
    Yes 239 6.47  1.2  
    No 360 6.42  1.2  
112 
 
     
Supplemental Table, continued   
Characteristics Number of Sleep Duration (hours)  
 participants Mean SD p-value* 
     
Hypertension (by JNC VI, 1997)    0.4 
    Yes 358 6.40  1.2  
    No 242 6.49 1.1  
Diabetes (% distribution)    <0.05 
    Yes 248 6.32 1.2  
    No 348 6.52 1.2  
Depression CESD >16 (% distribution)    0.5 
    Yes  97 6.36  1.3  
    No 492 6.46  1.1  
Hostility (% distribution)    0.2 
    Lowest  tertile 188 6.54  1.0  
    Second tertile 238 6.39 1.2  
    Highest tertile 153 6.31 1.3  
Use of Oral Steroids (%)    0.4 
    Yes 8 5.95  1.7  
    No 592 6.44 1.2  
Use of Inhaled Steroids (%)    <0.01 
    Yes 15 5.57 1.0  
    No 585 6.46 1.2  
Use of any Antihypertensive Med (%)    0.1 
    Yes 340 6.37 1.2  
    No 260 6.53 1.1  
Use of HRT (%)    0.1 
    Yes  18 6.90  1.0  
    No 582 6.42  1.2  
Use of any Antidepressant (%)    0.01 
    Yes  66 6.77 1.3  
    No 534 6.39 1.2  
Any insomnia symptom (%)     0.3 
    Yes 209 6.37 1.2  
    No 382 6.48 1.1  
All apneas and hypopneas **    0.2 
   AHI ≥ 15  323 6.38 1.2  
   AHI < 15  218 6.53 1.1  
Mean (SD) Sleep efficiency (%)      <0.0001 
   Efficiency < 85%   60 5.71 1.1  
   Efficiency ≥ 85%  540 6.51 1.2  
*
 t-test or ANOVA test or Kruskall Wallis 
**






Supplemental Table C-7  Percent differences (95% confidence intervals) in features of the daily cortisol 
associated with sleep duration (≥3 hours to <9 hours) and sleep efficiency (%), specified as continuous, 
MESA Study 
 Sleep Durationa  Sleep Efficiencyb 
 (1 hour less) (1% less) 
Percent difference in wake-up (CI 95%) 
Model 1c −5.67 (−12.7, 0.9) −1.52 (−4.1, 1.0) 
Model 2d   −4.67 (−12.5, 2.6) −1.84 (−4.7, 0.9) 
Model 3e −4.23 (−12.3, 3.2) −2.01 (−4.9, 0.8) 
Model 4f −2.68(−10.3, 4.5) −1.80 (−4.7, 1.0) 
Percent difference in cortisol awakening response 
Model 1c −3.10 (−10.3, 3.6) −0.39 (−2.9, 2.0) 
Model 2d −2.40 (−10.2, 4.8) −0.16 (−2.9, 2.5) 
Model 3e −3.13 (−11.4, 4.5) −0.10 (−2.9, 2.6) 
Model 4f −3.27 (−11.0, 3.9) 0.13 (−2.5, 2.8) 
Percent difference in early decline 
Model 1c 2.08 (−3.5, 8.0) 1.84 (0.1, 3.6)§ 
Model 2d 0.65 (−5.2, 6.8) 1.98 (0.3, 3.7)§ 
Model 3e −0.06 (−6.5, 5.9) 2.09 (0.3, 3.9)§ 
Model 4f −1.92 (−8.5, 4.3) 2.23 (0.4, 4.1)§ 
Percent difference in late decline 
Model 1c 0.92 (0.4, 1.5)** −0.08 (−0.2, 0.1) 
Model 2d 1.02 (0.5, 1.6)** −0.09 (−0.2, 0.1) 
Model 3e  1.13 (0.6, 1.7)*** −0.08 (−0.2, 0.1) 
Model 4f  1.28 (0.7, 1.9)*** −0.17 (−0.3, 0.0) 
Summary measures   
Percent difference in wake-to-bed slope  
Model 1c 0.99 (0.52, 1.46)*** −0.06 (−0.07, 0.19) 
Model 2d 1.00 (0.50, 1.50)***   0.07 (−0.07, 0.20) 
Model 3e 1.02 (0.50, 1.54)***   0.08 (−0.05, 0.22) 
Model 4f 1.01 (0.47, 1.55)**   0.01 (−0.14, 0.15) 
Percent difference in AUC  
Model 1c −0.06 (−5.23, 4.85) 0.16 (−1.33, 1.68) 
Model 2d   0.22 (−5.13, 5.88) 0.20 (−1.45, 1.87) 
Model 3e −0.36 (−6.05, 5.02) 0.29 (−1.41, 2.01) 
Model 4f −0.65 (−6.58, 4.94) 0.34 (−1.42, 2.14) 
§<0.05;   *≤0.01;   **≤0.001 ;   ***≤0.0001 
 
a  Sleep duration was estimated as continuous (hours)   
b Sleep efficiency was estimated as percentage (%)   
 
Models: 
c Model 1 : Model adjusted for day of saliva collection, time of wake-up, gender, age, race/ethnicity, and income-
wealth index    
d Model 2 : Model 1 + body mass index, smoking, alcohol consumption, medications (oral and inhaled   steroids, 
hormone replacement therapy and antidepressants) and apnea/hypopnea index (AHI) 
e Model 3 : Model 2 + hypertension, diabetes, and depression 
f  Model 4 : Model 3 + sleep efficiency (as continuous) or sleep duration (as continuous) in models for sleep duration 




Supplemental Table C-8  Percent differences (95% confidence intervals) in features of the daily cortisol 
associated with sleep duration specified as dichotomized and continuous when participants were 
restricted to sleep duration < 8 hours 
 Sleep Duration  
 Dichotomizeda Continuousb 
 (<6 hr vs. ≥6 hr) (1 hour less) 
Percent difference in wake-up (CI 95%) 
Model 1c -12.08 (-31.2, 4.3) −6.94 (−14.8, 0.4) 
Model 2d −13.25 (−35.1, 5.0) −5.924 (−14.5, 2.0) 
Model 3e −12.03 (−34.3, 6.5) −5.80 (−14.8, 2.5) 
Model 4f −9.16 (−30.4, 8.6) −3.99 (−12.5, 3.9) 
Percent difference in cortisol awakening response 
Model 1c −8.76 (−25.5, 5.8) −3.97 (−12.7, 4.1) 
Model 2d −8.35 (−27.1, 7.6) −3.64 (−13.1, 5.01) 
Model 3e −9.74 (−29.2, 6.8) −4.80 (−14.81, 4.31) 
Model 4f −9.67 (−28.3, 6.3) −4.85 (−14.3, 3.81) 
Percent difference in early decline 
Model 1c 7.55 (−3.9, 20.3) 4.38 (−1.95, 11.1) 
Model 2d 8.62 (−4.1, 23.1) 4.49 (−2.45, 11.9) 
Model 3e 8.14 (−5.0, 23.0) 3.95 (−3.4, 11.89) 
Model 4f 4.82 (−7.6, 19.0) 1.81 (−5.44, 9.6) 
Percent difference in late decline 
Model 1c 1.55 (0.3, 2.8)§ 0.63 (0.0, 1.2)§ 
Model 2d 1.62 (0.2, 3.0)§ 0.61 (−0.0, 1.2) 
Model 3e 1.57 (0.2, 3.0)§ 0.66 (−0.0, 1.3) 
Model 4f 1.79 (0.4, 3.2)§ 0.81 (0.1, 1.5)§ 
Percent difference in wake-to-bed slope  
Model 1c 1.93 (0.8, 3.0)** 0.88 (0.3, 1.4)* 
Model 2d 2.14 (1.0, 3.3)** 0.89 (0.3, 1.5)* 
Model 3e 2.03 (0.8, 3.2)** 0.87 (0.3, 1.5)* 
Model 4f 1.99 (0.8, 3.2 ** 0.85 (0.2, 1.5)* 
 §<0.05;   *≤0.01;   **≤0.001 ;   ***≤0.0001 
a  Sleep duration was estimated as dichotomized (short sleep duration (<6hours) ) vs. longer sleep duration 
(reference,  ≥ 6hours to < 8 hours) 
b Sleep duration was estimated as continuous (3 to < 8 hours) 
 
Models: 
c Model 1 : Model adjusted for day of saliva collection, time of wake-up, gender, age, race/ethnicity, and income-
wealth index    
d Model 2 : Model 1 + body mass index, smoking, alcohol consumption, medications (oral and inhaled   steroids, 
hormone replacement therapy and antidepressants) and apnea/hypopnea index (AHI) 
e Model 3 : Model 2 + hypertension, diabetes, and depression 






Supplemental Table C-9  Percent differences (95% confidence intervals) in wake−to−bed slope of 
salivary cortisol level associated with sleep duration dichotomized at 5 hours (first column) and at 7 hours 
(second column) for the overall sample and when restricted, MESA 
 Sleep Duration 
Dichotomizeda  
   
 cut off 5 HRS cut off 7HRS 
Whole sample     
  Model 1c 1.08 (−0.7, 2.9) 2.04 (1.1, 3.0)*** 
  Model 2d 0.93 (−0.9, 2.8) 2.11 (1.1, 3.1)*** 
  Model 3e 0.75 (−1.2, 2.7) 2.28 (1.3, 3.3)*** 
  Model 4f 0.59 (−1.4, 2.6) 2.22 (1.2, 3.3)*** 
   
Restricted to 8 hours (≥ 3 to < 8 hrs)b  
  Model 1c 0.9 (−0.8, 2.7) 1.65 (0.6, 2.7)** 
  Model 2d 0.8 (−1.1, 2.7) 1.75 (0.7, 2.8)** 
  Model 3e 0.6 (−1.3, 2.6) 1.85 (0.8, 2.9)** 
  Model 4f 0.5 (−1.5, 2.5) 1.80 (0.7, 2.9)** 
     
*
≤ 0.01    
**
≤ 0.001   
***
≤ 0.0001 
a Sleep duration was dichotomized (short sleep duration (<5 or <7 hours, ) vs. longer (reference,  ≥ 5, or ≥7 hours, 
respectively).  
b Sample restricted to < 8 hours of sleep duration 
 
Models: 
c Model 1 : Model adjusted for day of saliva collection, time of wake−up, gender, age, race/ethnicity, and 
income−wealth index    
d Model 2 : Model 1 + body mass index, smoking, alcohol consumption, medications (oral and inhaled   steroids, 
hormone replacement therapy and antidepressants) and apnea/hypopnea index (AHI) 
e Model 3 : Model 2 + hypertension, diabetes, and depression 












1082 participants, 1082*2=2164 days, 1082*2*8 = 17312 salivary samples 
Excluded days with no time of collection for entire day 
→ 1080 participants, 2158 days, 17264 samples   
Excluded days with no cortisol value for entire day  
→  1069 participants, 2134 days, 17072 samples  
Excluded samples with missing cortisol value or time of collection 
 → 1069 participants, 2134 days, 16032 samples  
Excluded samples with  0 nmol/L and >100 mmol/L) 
 → 1069 participants, 2132 days, 15915 samples  
Excluded participants with no measure of sleep duration by 
actigraphy  →   622 participants  
Excluded participants who had ≤3 hours of sleep and >9 hours 
→ 600 participants, 1198 days, 8985 samples 
117 
 
Supplemental Figure C-2  LOESS Plot log transformed cortisol by sleep duration 
 
Note: Short sleepers had lower cortisol at awakening and at 30 minutes after as well as slower decline later in 
the day and higher levels of cortisol at bedtime than longer sleepers. 













Subjective Sleep Quality: Insomnia vs. Non-insomnia 
















APPENDIX D Chapter 4  
Supplemental Table D-1  Characteristics of participants (n= 527) by sleep duration at < 6 hours, between 
6 and less than 7 hours and 7 or more hours, MESA 
 Sleep Duration (hours)¶  
 
< 6 hours 6 to < 7 hours ≥7 hours P* 
 (n=173) (n=185) (n=169)  
 N(%) or Mean ± SD)  
Demographics     
Age (years) 67.7±9.2  68.1±8.3 69.0±8.9 .44 
Male  86(50) 91(49) 65 (39) .06 
Race/ethnicity      
     White 27 (16) 48 (26) 68 (40) <.0001 
    Black 78 (45) 59 (32) 26 (15) 
     Hispanic 68 (39) 78 (42) 75 (44) 
 Income-Wealth Index 3.9±2.2 4.5±2.2 4.4±2.3 .03 
Lifestyle Characteristics     
BMI 30.7±5.8 29.6±5.1 28.1±4.6 <.0001 
Current smokers 19 (11) 14 (8) 11 (7) .52 
Alcohol consumption 65 (38) 74 (40) 76 (45) .39 
Hypertension  106 (61) 103 (56) 99 (59) .56 
Diabetes 67 (39) 84 (46) 58 (35) .10 
Depression CESD >16 36 (21) 23 (13) 25 (15) .08 
Steroids1 users 14 (8) 2 (1) 3 (2) <.001  
Antihypertensive  users 104 (60) 99 (54) 93 (55) .42 
Hormone therapy users 4 (2) 7 (4) 9 (5) .35 
Antidepressant users 2 15 (9) 17 (9) 27 (16) .06 
Sleep Variables 
    Sleep efficiency <85% 29 (17) 20 (11) 5 (3) <.0001 
Insomnia symptom3 68 (40) 58 (32) 58 (35)  .25 
AHI4 ≥ 15 93(62) 96(56) 88(57) .52 
Naps5 (min/day) 61±51 34±33 30±34 <.0001 
¶ Sleep duration in this sample were between > 3 hours and < 9 hours 
*either chi-square or t-test/ANOVA or Kruskall Wallis test for variables non-normally distributed       
1 oral and inhalers 
2 including medication for sleep and mood (including benzodiazepines) 
3 WHIIRS score ≥ 9 = insomnia  
4AHI = all apneas and hypopnea per hour of the sleep with ≥ 3% or greater desaturation – index; 





















































































































































   
   














   
   













   
   














   
   























































































































































































































































































































































































   
   
   











   
   
   













































































































































































































































































































































































































































































































































































































































































































































































   
   














   
   



















   
   














   
   






































































































































































































































































































































































   
   
   











   
   
   























































































































































































































































































































































































































































































































































































































































































































   
   














   
   



















   
   














   
   








































































































































































































































































































































































   
   
   











   
   
   
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplemental Figure D-4 Mean log-transformed cortisol (log nmol/L) during the stress challenge protocol 










Supplemental Figure D-5 Mean log-transformed cortisol (log nmol/L) during the stress challenge protocol 
by demographics, MESA Stress 
 
















Heart Rate by Age - Males 
 
 
 
 
 
 
 
